Reversal of Inflammation-Induced Bone Loss and Vascular Pathology by Dried Plum's Polyphenols by Rendina, Elizabeth
   REVERSAL OF INFLAMMATION-INDUCED BONE 




   By 
   ELIZABETH RENDINA 
   Bachelor of Science in Biochemistry  
   Oklahoma State University 
   Stillwater, OK 
   2007 
 
 
   Submitted to the Faculty of the 
   Graduate College of the 
   Oklahoma State University 
   in partial fulfillment of 
   the requirements for 
   the Degree of 
   MASTER OF SCIENCE  
   May, 2009  
   REVERSAL OF INFLAMMATION-INDUCED BONE 





   Thesis Approved: 
 
 
   Dr. Brenda J. Smith 
   Thesis Adviser 
 
   Dr. Stephen L. Clarke 
 
Dr. Edralin A. Lucas 
 
  Dr. A. Gordon Emslie 









 I would like to start off by thanking my major advisor Dr. Brenda Smith who 
provided me with many different support systems which all played a significant role my 
degree.  Dr. Smith became more than a mentor to me, she took me under her wing and 
created an environment which I was able to thrive in.  I cannot express enough gratitude 
to her for this opportunity and for allowing me to find something I am truly passionate 
about. 
 I would also like to thank my committee members, Dr. Stephen Clarke and Dr. 
Edralin Lucas.  They played a vital role in the completion of my degree, as well as 
offering their support and guidance any time I needed it.  Along with my committee 
members, I’d like to thank the other faculty in the Nutritional Science Department, who 
were always willing to assist me in any way they could and I have always appreciated 
that. 
 Lastly I’d like to thank my family who I have always had a unique bond with.  
My nephew and niece, who always bring a smile to my face and I cannot express enough 
how much I love and enjoy them.  My sister, Andrea, who is always there to support me 
and is the “big sister” every girl wants.  Finally my parents, who are and have always 
been so supportive of me and all my endeavors.  My mom and dad have continued to 
support my dreams no matter how they have changed throughout the years, and are 
always willing to help me in whatever possible.  My family has played huge part in my 
successes and I feel every goal I accomplish in life is a direct reflection on them.  
 iii 
TABLE OF CONTENTS 
 
Chapter          Page 
 
I. INTRODUCTION ......................................................................................................1 
 
 Introduction ..............................................................................................................1 
 Hypothesis................................................................................................................6 
 Objectives ................................................................................................................7 




II. REVIEW OF LITERATURE....................................................................................9 
  
 Introduction to Osteoporosis and Cardiovascular Disease ......................................9 
 Populations at Risk for Osteoporosis and Cardiovascular Disease .......................10 
 CVD and Osteoporosis: Common Complications of Chronic  
   Inflammatory Conditions .....................................................................................12 
 Inflammation in Osteoporosis and CVD................................................................16 
 Animal Models of Chronic Inflammation, Bone Loss, and  
   Vascular Disease ..................................................................................................21 
 Pharmacological Treatment Options for Osteoporosis and CVD ..........................22 




III. METHODOLOGY ................................................................................................30 
 
 Animal Care ...........................................................................................................30 
 Implantation of Pellets ...........................................................................................31 
 Extraction of Polyphenols from Dried Plum Powder ............................................32 
 Total Phenolic Analysis and Diet Formulation ......................................................32 
 BMD Assessment Using DXA ..............................................................................33 
 Micro-computed Tomography Analysis ................................................................33 
 Finite Element Analysis .........................................................................................34 
 RNA Extraction and Quantitative Real-Time PCR ...............................................34 
 Histology ................................................................................................................35 
 Statistical Analysis .................................................................................................36 
 
 iv 
Chapter          Page 
 
IV. FINDINGS .............................................................................................................41 
 
 Bone Mass and Densitometry ................................................................................41 
 Proximal Tibia Trabecular and Cortical Bone Microarchitecture .........................41 
 Biomechanical Properties of Trabecular Bone ......................................................42 
 Gene Expression of Whole Femurs .......................................................................42 
 Histological Evaluation of the Myocardium and Aorta .........................................44 
 
V. DISCUSSION .........................................................................................................71 
 
 
VI. CONCLUSIONS ...................................................................................................76 
 
 Summary of Findings .............................................................................................76 
 Conclusions ............................................................................................................77 








 University of Oklahoma Health Sciences Center IACUC .....................................95 




LIST OF TABLES 
 
 
Table           Page 
 
   1   Treatment Groups ................................................................................................37 
   2   Formulation of Diet..............................................................................................38 
   3   Primer Sequences used for Real Time-PCR ........................................................39 
   4   Bone Mineral Area (BMA) and Content (BMC) of Tibia ...................................46 
   5   Tibia Trabecular Bone Microarchitectural Parameters  
 at Baseline and Following 2 or 6 Weeks of Dietary Treatments ..........................47 
   6   Cortical Bone Morphometry at the Tibial Mid-diaplysis at Baseline ..................48 
   7   Cortical Bone Morphometry at the Tibial Mid-diaphysis After  
 2 or 6 Weeks of Dietary Treatments ....................................................................49 
   8   Biomechanical Properties of the Tibia as Assessed by 
 Finite Element (FE) Analysis at Baseline and Following  
 2 or 6 Weeks of Dietary Treatments ....................................................................50 
   9   Histological Scoring of the Myocardium 2 Weeks Post  
 Dietary Treatments of the Large and Small Arteries and Arterioles ....................51 
 10   Histological Scoring of the Myocardium 2 Weeks Post 
 Dietary Treatments for Cellular Infiltration and Infarction ..................................52 
 11   Histological Scoring of the Myocardium 6 Weeks Post  
 Dietary Treatments of the Large and Small Arteries and Arterioles ....................53 
 12   Histological Scoring of the Myocardium 6 Weeks Post  
 Dietary Treatments for Cellular Infiltration and Infarction ..................................54 
 13   Histological Scoring of the Aorta Following 2 or 6 Weeks  
 of Dietary Treatments ...........................................................................................55 




LIST OF FIGURES 
 
Figure           Page 
 
   1   Experimental Design ............................................................................................40 
   2   Bone Mineral Density (BMD) of Excised Tibia ..................................................56 
   3   Baseline Microarchitectural Paramaters of Trabecular  
 Bone at the Proximal Tibia ...................................................................................57 
   4   2 Week Microarchitectural Parameters of Trabecular  
 Bone at the Proximal Tibia ...................................................................................58 
   5   6 Week Microarchitectural Parameters of Trabecular  
 Bone at the Proximal Tibia ...................................................................................59 
   6   Gene Expression of Inflammatory Mediators at Baseline ...................................60 
   7   Gene Expression of Key Genes Involved in Bone  
 Resorption at Baseline ..........................................................................................61 
   8   Gene Expression of the Bone Formation Marker  
 Alkaline Specific Phosphatase at Baseline ...........................................................62 
   9   Inflammatory Mediators 2 Weeks Post Dietary Treatments ................................63 
  10  Gene Expression of Key Genes Involved in Bone Resorption  
 at 2 Weeks of Dietary Treatments ........................................................................64 
  11  Gene Expression of the Bone Formation Markers at  
 2 Weeks of Dietary Treatments ............................................................................65 
  12  Gene Expression of Inflammatory Mediators at 6 Weeks  
 of Dietary Treatments ...........................................................................................66 
  13  Gene Expression of Key Genes Involved in Bone  
 Resorption at 6 Weeks Post Dietary Treatments ..................................................67 
  14  Gene Expression of the Bone Formation Marker Alkaline 
 Specific Phosphatase at 6 Weeks of Dietary Treatments  ....................................68 
  15   Histological Evaluation of Cellular Infiltration of  
 the Myocardium 6 Weeks After Dietary Treatments ...........................................69 
  16  Histological Evaluation of the Aorta 6 Weeks  
















Even with advances in modern medicine, osteoporosis and cardiovascular 
diseases (CVD) are still considered major public health threats.  By definition, 
osteoporosis is a disease characterized by low bone mass, as indicated by bone mineral 
density (BMD) measures, and structural deterioration of bone microarchitecture to the 
point that fracture risk is increased.  Recent estimates indicate that over 43 million 
Americans have been diagnosed with osteoporosis or low bone mass (i.e. osteopenia) (1).  
By comparison, CVD include a wide range of conditions that involve the myocardium 
and/or vascular system.  One of the most common CVD, coronary artery disease, is a 
contributing factor in approximately 29% of all American deaths (2).  Both osteoporosis 
and CVD are considered age-related diseases in that they evolve over time and age is 
considered a major risk factor.  This is demonstrated by the fact that osteoporosis is more 
common in individuals over the age of 50, and CVD increases significantly after the age 
of 50 (2). The predicted demographic shift toward an older society in the U.S. would 
suggest that the prevalence of these diseases will only increase unless better prevention 
and treatment strategies are developed (1).  
 Clinical observations suggest that chronic activation of the immune system is 
likely involved in the development of osteoporosis and CVD (3).  In recent years, studies 
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have shown that in postmenopausal women, a population in which bone loss and 
increased risk for CVD are well documented, a marked increase in the pro-inflammatory 
cytokines occurs (4).  Additionally, patients with chronic inflammatory conditions such 
as systematic lupus erythematosus (SLE) and rheumatoid arthritis (RA), often experience 
complications of bone loss and CVD (5-8).  Women with SLE have been shown to be at 
greater risk of having developing osteoporosis (6) and autopsy studies indicate a high 
incidence of atherosclerotic lesions (9).  Likewise, patients with RA experience bone loss 
throughout the skeleton as well as in the affected  joints, and have reduced life-
expectancy due in part to increased CVD mortality (7).  Elevated levels of circulating 
pro-inflammatory mediators such as interleukin (IL)-1 and IL-6, tumor necrosis factor 
(TNF)-α, and macrophage colony stimulating factor (M-CSF) are common in many of 
these inflammatory conditions as well as in postmenopausal women as estrogen levels 
decline (10). 
At the tissue level, chronic inflammation creates a bone catabolic and vascular 
pro-atherosclerotic environment.  In the bone, increased bone resorption by osteoclasts 
and decreased bone formation by osteoblasts are likely due to the increase in cytokines 
and growth factors that up-regulate osteoclast development and  activity, and suppress 
osteogenesis (4).  If such alterations in bone metabolism persist, deterioration of bone 
tissue and bone loss will result.  Within the vascular walls, immune cells such as 
monocytes and macrophages produce cytokines which have been identified in all stages 
artheromatous lesions.  Several of the same inflammatory mediators that play a role in 
bone loss such as IL-1, IL-6, interferon (IFN)-γ, TNF-α, several growth factors, are also 
involved in vascular disease (11).  Both male and female patients with CVD exhibit much 
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higher serum IL-6 and TNF-α than those without CVD (12).  Continued research is 
focused on establishing a better understanding the role of these mediators in osteoporosis 
as well as CVD. 
Accumulating evidence over the past six decades has suggested that the 
pathophysiology of both osteoporosis and CVD may be related (13-18).  Individuals with 
low BMD have been shown to have a higher incidence of CVD (19).  Hyder et al., found 
an inverse relationship between  patient’s lumbar spine BMD and aortic calcification 
(18).  Postmenopausal women that have been diagnosed with osteoporosis tend to have 
elevated arterial stiffness, predisposing them to a higher risk of developing CVD (20). 
Based on the role of inflammation in the pathophysiology of osteoporosis and CVD, it 
seems reasonable that chronic elevation of pro-inflammatory mediators may provide a 
link between these two conditions.   
Recently, an animal model of chronic low grade inflammation was developed for 
the purpose of studying the effects of low grade inflammation on bone (21).  This model 
was first developed in 3 month-old Sprague Dawley rats that received lipopolysaccharide 
(LPS) over 90 days via a slow release pellet implanted on the dorsal region of the neck 
(21).  Chronic inflammation was verified by increased monocyte and neutrophil counts in 
the peripheral blood over the 90 day study period.  This chronic inflammatory state was 
associated with a decrease in femur BMD and loss of trabecular bone at the proximal 
tibia (21).  Further investigation revealed that chronic exposure to LPS also produced a 
cardiovascular pathology characterized by vascular fibrosis and disruption of the intimal 
layer of the smaller intramural arteries and arterioles of the myocardium (22).  
Subsequent studies in mice revealed a similar bone and vascular pathology in the 
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C57BL/6 mouse after 30 and 90 days (23, 24).  Evidence from these initial studies 
demonstrated that this model provided a system to study the role of chronic inflammation 
in concurrent bone loss and vascular disease. 
 Theoretically, if inflammatory pathways are the primary mediators of bone loss 
and vascular disease, therapeutic agents which have anti-inflammatory properties would 
serve as an ideal treatment.  Statins are a group of drugs commonly prescribed because of 
their efficacy in lowering serum cholesterol.  This class of drugs primarily acts by 
inhibiting the enzyme HMG-CoA  reductase, which catalyzes the conversion of HMG-
CoA to the cholesterol precursor, mevalonate (25).  More recent studies have suggested 
that these lipid lowering drugs also have  anti-inflammatory properties that may protect 
against both osteoporosis and CVD (26, 27).  In terms of osteoporosis, statin therapy has 
been associated with an increase in BMD and has positive effects on fracture healing (26) 
and bone resorption (28).  Statins have also been shown to increase bone formation in 
vitro by stimulating bone morphogenetic protein 2 (BMP2), a growth factor that 
promotes osteoblast differentiation (29).  In terms of CVD, pro-inflammatory cytokines 
participate in atherothrombotic events and it has been suggested that statins may reduce 
the risk of CVD not only through their positive effects on the lipid profile, but also by 
their effects on these cytokines (30).  While statins provide a potential therapeutic option 
that could be beneficial in the treatment of both cardiovascular and skeletal health, they 
are not without some undesirable side effects (e.g. muscle pain/weakness, liver damage).  
Therefore, natural treatment options that could be incorporated into the diet may provide 
a more desirable alternative for many individuals. 
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Plant-based foods such as fruits and vegetables and their bioactive components, 
are of particular interest due to their ability to reduce the occurrence of bone loss and 
cardiovascular disease.  Dried plums are of particular interest due to their rich source of 
several nutrients (i.e. potassium, boron, and magnesium) and their polyphenolic 
compound content (31).  Dietary supplementation with dried plum has been shown to 
prevent and, to some extent, reverse the loss of bone mass (i.e., BMD) in ovariectomized 
young adult rats (32, 33).  Dried plum’s osteoprotective effects were also studied in male 
orchidectomized rats and were found to down-regulate the gene expression of both 
osteoprotegerin (OPG) and receptor activator for NF-κB ligand (RANKL), and prevent 
the gonadal hormone deficiency-induced deterioration of trabecular bone 
microarchitecture (34).  In vitro studies using polyphenols extracted from dried plum 
indicated that these compounds may enhance osteoblastic activity (35), and suppress 
osteoclastogenesis (36).  In addition to its effects on bone, dried plum has also been 
shown to impact risk factors for CVD.  Tinkerand colleagues., (37) administered dried 
plums to men with mild hypercholesterolemia, and found that they were able to reduce 
total cholesterol.  Dried plums have also been shown to protect against the ovariectomy-
induced elevation of total cholesterol in rats fed a high dried plum diet (25% w/w) had 
lower levels of total liver lipids (38).  These findings suggest that dietary supplementation 
with dried plum is able to exert beneficial effects both on both the skeletal and vascular 
system. 
One particular group of compounds found in fruits and vegetables, polyphenols, 
have been of particular interest due to their anti-inflammatory and antioxidant properties 
(39).  Polyphenols are a class of phytochemicals found in high concentrations in plant-
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based foods which are responsible for a fruit/vegetable’s vibrant color and offer a natural 
defense mechanism for plants (39).  Red wine, a rich source of the polyphenolic 
compound resveratrol has been shown to reduce the incidence of CVD and at the same 
time stimulate proliferation and differentiation of osteoblasts (40).  The polyphenolic 
compound found in high concentrations in green tea, (-) –epigallocatechin-3-gallate 
(EGCG), has been shown to dramatically decrease the number of osteoclasts in vitro (41) 
and is inversely related to mortality due to CVD (42).  The mechanism by which green 
tea exerts its positive effects appear to be anti-oxidative, anti-inflammatory, and anti-
atherosclerotic (43).  Furthermore, soy, another rich source of polyphenols (e.g. genistein 
and daidzine), has been shown to have protective effects on bone (44), and prevent the 
formation of atherosclerotic lesions (45).  Therefore, it is reasonable to expect that dried 
plum’s polyphenols may offer protection and perhaps could even reverse the detrimental 
effects on the skeletal and cardiovascular systems. 
In this study, we propose to induce bone loss and vascular pathology due to 
chronic low grade inflammation, and that dried plum’s polyphenols will be able to 
attenuate this response.  The following hypothesis will be tested and the objectives 
carried out to accomplish this purpose.  
 
Hypothesis:  Polyphenol extract from dried plums will reverse the bone loss and vascular 
pathology induced by low grade chronic inflammation by reducing key inflammatory 
mediators (e.g. TNF-α and Il-6) involved in the pathophysiology of osteoporosis and 
CVD.   
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Objective 1:  X-ray microcomputed tomography (μCT) and dual-energy x-ray 
absorptiometry (DXA) will be used to assess the alterations in trabecular and cortical 
bone microarchitecture and bone mineral content and density in response to inflammation 
and dried plum’s polyphenols.  The effects of dried plums’ polyphenols will be compared 
to those of the whole dried fruit and the cholesterol-lowering drug simvastatin (25 mg/kg 
diet) will be used as a positive control. 
 
Objective 2:  To determine the extent to which dried plum’s polyphenols reverse the 
pathological changes occurring in the myocardium and vasculature in response to 
inflammation, histological evaluation will be performed.  The influence of dried plums’ 
polyphenols on cardiovascular pathology will be compared to that of similar doses of 
dried plum and simvastatin. 
 
Objective 3:  To assess the local and systemic effects of dried plum’s polyphenols on 
genes involved in the regulation of bone formation and resorption.  The effects of dried 
plum’s polyphenols on these indicators of bone resorption (TRAP, RANKL, OPG) and 
formation (ALP, IGF-1) will be compared to that of dried plum and simvastatin.  
 
Objective 4:  To determine the extent to which polyphenols extracted from dried plums 
transcriptionally alter local and systemic inflammatory mediators.  TNF-α, IL-6 and IL-
10 gene expression will be assessed to determine the effect different treatment options 
have on these two inflammatory-induced conditions, using of real time PCR.  The effects 
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of the polyphenols on these inflammatory mediators will be compared to that of dried 




 Our laboratory has developed the animal model proposed in this study to examine  
the effects of chronic low grade inflammation (21-23, 46).  Previously this model has 
been shown to closely mimic some of the effects of chronic inflammation on the skeletal 
and vascular system in humans.  Although the use  of in vivo  model has advantages 
compared to cell or tissue culture systems, results from this study cannot be directly 
extrapolated to humans.  It is well documented that effects observed in rodent animal 
models may vary to some extent with the responses observed in humans.  Animal models 
are also convenient means for researchers to perform initial studies of various dietary 
regimens, however in humans, adherence to study protocol may be problematic.   
 Another potential limitation to this study is the fact that total polyphenols were 
extracted from dried plums.  While the extract was analyzed for its polyphenolic, 
carbohydrate, fat and proetin content, other components may remain in this sample and 
potentially influence the results.  Polyphenol content of dried plum may vary by season 
and other harvesting techniques, which may alter potency of the dried plum’s 
polyphenols.  This study used a single lot of dried plum powder provided by California 





REVIEW OF LITERATURE 
 
Introduction to Osteoporosis and Cardiovascular Diseases 
 
Mounting clinical evidence and epidemiological studies suggest a link between 
osteoporosis and CVDs such as atherosclerosis, cerebral vascular incidence, peripheral 
arterial disease (PAD), and coronary heart disease (17, 18, 47-49).  Both conditions are 
major public health problems for developed countries such as the United States and many 
European countries (50).  Coronary artery disease is the leading cause of death for both 
men and women in the U.S. (51), and osteoporosis affects an estimated is 10 million 
Americans, with another 34 million at risk (i.e. osteopenia or low BMD) (1).  European 
countries have the highest prevalence of osteoporosis.  For example Denmark has a 
population of approximately 5.46 million people and 29.3%  (1.6 million) are affected by 
osteoporosis (52).  CVD is an even greater public health concern in that an estimated 17.5 
million people die from cardiovascular disease per year worldwide, representing 30% of 
all deaths globally (50).   
 
 Osteoporosis and CVD are debilitating conditions that affect a patients “physical” 
health, as well as having a significantly economic impact on the healthcare system. The 
annual costs associated with CVDs and osteoporosis in the United States have been
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estimated at $403.1 billion (53) and $16.9 billion, respectively (54).  Combined, these 
two age-related chronic conditions contribute approximately $420 billion to the total U.S. 
healthcare expenditures (53, 54).  The total direct costs of osteoporosis in European 
countries was estimated at $41 billion per year (€31.7 billion/year) (55), and overall CVD 
is estimated to cost Europeans $248.3 billion (€192 billion/year) per year (56).  The 
debilitating nature of the age-related conditions as well as the economic burden to 
healthcare systems has motivated researchers and healthcare professionals to improve the 
prevention and treatment strategies.   
To date, patients diagnosed with osteoporosis have the option of anti-resorptive 
bisphosphonate drugs or anabolic parathyroid hormone (PTH) therapy, which are focused 
on altering bone metabolism.  Treatment for CVD is dependent on the specific disease 
pathology (e.g., coronary artery disease, hypertension, or stroke), and effective treatments 
usually include lifestyle behavior modifications.  For example, patients diagnosed with 
atherosclerosis may be prescribed a variety of medications, one of the most commonly 
prescribed drug classes is the cholesterol loweringc statins.  A single patient diagnosed 
with both a CVD and osteoporosis will most likely be prescribed separate drugs (e.g., an 
anti-resorptive drug combined with lipid-lowering and anti-hypertensive agents) which 
ultimately lead to polypharmacy.  This scenario is quite common due to the tendency for 
these conditions occur simultaneously (57).   
Populations at Risk for Osteoporosis and CVDs 
Increased risk for osteoporosis and CVD occurs in populations such as the 
elderly, postmenopausal women, and people with chronic inflammatory conditions.  For 
instance, as individuals age, skeletal deterioration and the risk for CVD increase.  In fact 
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55% of the people 50 years of age and older have osteoporosis in America and about 84% 
of cardiovascular disease deaths occur in people age 65 and older (1, 2).  Mussolino et 
al., (1) reported that in a cohort of Caucasian men, phalangeal BMD was inversely 
associated with cardiovascular-related deaths.  Farhat and colleagues (2) found that the 
incidence of CVD in older men and women (i.e. aged 68-80 years) was also inversely 
related to BMD of the hip, femoral neck, trochanter, and spine with CVD (2).  Browner 
and colleagues (3) also studied women aged 65 years and older to determine how stroke 
risk would coincide with skeletal deterioration.  They determined that osteopenia was 
correlated with increased risk of stroke, but indicated that they did not believe the low 
BMD was causal (3).  
In addition to aging, diminished estrogen, associated with natural or surgical 
menopause, is also a major risk factor for osteoporosis and CVD.  Uyama and colleagues 
(4) found a negative correlation between carotid atherosclerosis and total BMD in 
postmenopausal women aged 67-85.  Von der Recke et al., (5) identified that low bone 
mineral content (BMC) in postmenopausal women as a risk factor for increased 
mortality, particularly from cardiovascular disease.  Low femoral neck BMD has been 
specifically associated with the incidence of PAD in postmenopausal women (6).  
Sumino et al., (7) showed that postmenopausal women with osteoporosis have elevated 
arterial stiffness, which may increase the risk of developing CVDs.  Sennerby and 
colleagues (8) designed a study to establish a common link between CVDs and 
osteoporosis.  They observed a significant increase in the incidence of hip fractures after 
the diagnosis of cardiovascular disease in postmenopausal women (8).  Hence, these 
studies indicate that in addition to the elderly, postmenopausal women are also a 
population at risk for concurrent osteoporosis and CVD.   
 Interestingly, aging and ovarian hormone deficiency are both associated with 
immunological changes (9, 10).  These changes include increased levels of pro-
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inflammatory cytokines, as well as a decrease in levels of anti-inflammatory cytokines 
(9,10).  Thus, as detailed in the following section a potential role of the immune system 
in the concurrent development of osteoporosis and CVD may be suggested by the fact 
that bone loss and vascular disease are common complications of chronic inflammatory 
conditions.   
 
CVD and Osteoporosis: Common Complications of Chronic Inflammatory 
Conditions 
 Conditions such as RA, COPD, periodontal disease, HIV and SLE are classified 
as chronic inflammatory diseases, and have been shown to have detrimental effects on 
both bone and vascular health.  One of the first inflammatory states in which bone 
deterioration was observed was RA.  Bone loss in RA occurs locally in the affected joints 
and systemically as pro-inflammatory cytokines (e.g., IL-1 and TNF-α) and proteinases 
are released resulting in cartilage and bone destruction (8).  Due to this relationship, RA 
disease activity is considered an independent risk factor for osteoporosis (58).  Attempts 
aimed at identifying the mechanism of RA associated bone loss have resulted in the TNF-
α superfamily molecule RANKL, also known as osteoclast differentiation factor, to be 
the focus of much research (59).  In addition to bone loss, RA patients are also at 
increased risk of developing CVD (60).  Kao et al., (61) found a higher prevalence of 
asymptomatic coronary artery calcium and CRP in women with RA.  A cohort study of 
1,010 patients with RA indicated the most frequent cause of death in this patient 
population was ischemic heart disease and myocardial infarction (7).  These observations 
are likely attributed to the fact that patients with RA have higher circulating pro-
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inflammatory cytokines which can have deleterious consequences on the skeletal and 
cardiovascular systems. 
 COPD is another chronic inflammatory condition in which osteoporosis and CVD 
are common complications (62).  As many as 72% of patients with COPD have been 
reported to be osteopenic, and estimates ranging from 36-60% of patients with COPD 
have osteoporosis (63). Nuti and colleagues (64) identified a strong association between 
the severity of COPD and fractures in men.  Sabit et al., (65) documented that increased 
arterial stiffness is related to the severity of airflow obstruction and may be a factor in the 
excess risk for CVD in COPD patients.  This same study revealed an increased aortic 
pulse wave velocity in patients with osteoporosis and the authors concluded that age-
related bone and vascular changes occur prematurely in COPD patients (65).  Moreover, 
Anthonisen et al., (66) found that CVD accounted for 42% of the first hospitalizations 
and 48% of second hospitalization in patients with mild COPD.  The results of these 
studies demonstrate that COPD is a disease in which the pro-inflammatory cytokines 
originating from the airways dramatically increase the risk of osteoporosis and CVDs. 
 Another chronic inflammatory condition in which bone loss and CVD 
complications are often observed are the periodontal diseases.  This group of infectious 
diseases results primarily from gram negative bacteria (such as, E. coli and S. shigella)  
Periodontitis is characterized by the destruction of connective tissue and dental bone 
support after an inflammatory host response secondary to infection by periodontal 
bacteria (67).  Severe periodontitis may result in tooth loss due to the loss of bone and 
other supporting tissues (67).  Kribbs and colleagues (68) were the first to report on the 
relationship between systemic BMD and mandibular density.  In this study, the 
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osteoporotic group had less mandibular bone mass and density in a thinner cortex then 
the control group (68).  Tezal and et al,. (69)  showed a strong correlation between the 
clinical severity of periodontal disease and BMD of the trochanter, Ward's triangle, and 
femur in postmenopausal women (69).  Furthermore, postmenopausal women with 
osteoporosis and low educational levels have a greater chance of having periodontal 
disease than do those without osteoporosis (70).  The major mechanism of periodontal 
diseases is the observed destruction of bone and cartilage, which has also been linked to 
increased risk of for CVD.  Inverse relationships have been shown in men between the 
number of teeth, coronary heart disease (71) and myocardial infarction (72).   
Bone demineralization and cardiovascular disease are also common complications 
among HIV infected patients, which is a relatively recent observation due to the dramatic 
improvement in life expectancy in this patient population.  Women with HIV have been 
shown to have a lower BMD of the lumbar spine and hip than women without HIV (73).  
In HIV-infected patients, alterations of both bone resorption and formation markers have 
been observed.  A relationship between CD4+ cell counts, low bone formation and 
elevated bone resorption have been proposed as the underlying pathophysiology of this 
bone deterioration (74).  With regard to cardiovascular health, the overall rate of  
incidence of PAH among HIV-infected individuals is 25-fold higher than in the general 
population (75).  Currier et al., (76) showed that the incidence of coronary heart disease 
among young men and women with HIV infection was significantly higher than in non-
HIV-infected individuals.  Hence data from HIV patients lend further support to the 
inflammation, osteoporosis, and CVD connection. 
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As a final example of a clinical condition in which immune dysfunction is 
associated with bone loss and vascular disease is evident in patients with SLE.  Studies 
suggest that women with SLE exhibit a lower BMD than healthy female population (74).  
Many factors contribute to this predisposition, including the systemic inflammatory 
response associated with the disease.  Almehed et al., (6) reported that in SLE patients 
(n=163) more than half had a lower BMD of the radius, lumbar spine or hip than 
expected and 23% were osteoporotic at one site or more (6).  The number of SLE patients 
experiencing osteopenia has drastically increased within the past decade, supporting that 
patients with SLE are at greater risk for developing osteoporosis and have a greater 
fracture risk (6).  In addition to bone loss, CVDs such as atherosclerosis, ischemic 
cerebral vascular event, and coronary heart disease are common in patients with SLE 
(77).  In a case-control study, Svenungsson and colleagues (5) showed a greater 
occurrence of atherosclerotic plaque among SLE cases compared with controls.  Not only 
was the incidence of plaque higher in this populations, but patients with SLE were more 
vulnerable for plaque rupture (78).  Pre-menopausal women with SLE are 50 times more 
likely to have a myocardial infarction compared with healthy women (79).  The more 
frequent incidence of CVDs and osteoporosis that occur in SLE patients may be due to 
on-going elevation of pro-inflammatory cytokines. 
Treatment options commonly used to in many of these chronic inflammatory 
conditions make it more difficult to discern the etiology of the skeletal and vascular 
pathology.  For example many RA, COPD, and SLE patients are treated with 
corticosteroids, such as glucocorticoid, due to their ability to suppress the immune 
response.  However, glucocorticoids have been shown to induce significant bone loss, 
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reduce bone strength, and ultimately increase the risk for osteoporotic fractures (80).  
Other undesirable side-effects of glucocorticoids potentially affecting the cardiovascular 
system include hyperglycemia and weight gain (80).  Another example of a class of drugs 
that may complicate interpreting the connection between chronic inflammatory 
conditions, CVD and osteoporosis are the highly active antiretroviral therapy (HAART) 
used to treat HIV-infected patients.  HAART have been associated with accelerated bone 
loss (81), but recently this concept has been brought into question (82).  Antiretroviral 
drugs have been associated with several metabolic side effects, such as dyslipidemia, 
impaired glucose metabolism and abnormal body fat distribution that may increase the 
risk of CVD in this patient population (83).  Hence, glucocorticoids and HAART are two 
examples of drugs used in the treatment of inflammatory conditions that may complicate 
our understanding of this relationship between inflammation, bone, and vascular health. 
 
Inflammation in Osteoporosis and CVD 
 Osteoporosis and CVD not only tend to occur simultaneously, but also share some 
very common features within their initiation and progression.  For decades it has been 
observed that patients with CVD have elevated pro-inflammatory cytokines and that 
CVDs can be classified as chronic inflammatory conditions.  The role of cytokines in the 
pathogenesis of cardiovascular disease has become increasingly evident as advances in 
our understanding of the role of the immune system in atherosclerosis and heart failure 
has evolved (84).  It was not until recently that osteoporosis which was traditionally 
considered a condition resulting from gonadal hormone deficiency was considered an 
immunological disorder (4).  However now many of the pro-inflammatory cytokines are 
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recognized as playing a critical role in normal bone remodeling and persistent increases 
in many of these cytokines is involved in the pathogenesis of osteoporosis in  peri- and 
postmenopausal women (85) and the elderly (84).   
The skeleton is a very complex system in which coupling of osteoblast activity or 
bone formation and osteoclast activity or bone resorption) is required to maintain strong 
bones that are resistant to fractures.  Uncoupling of bone resorption and formation can 
have a significant impact on bone quality and strength, thereby increasing the risk of 
fracture.  Pro-inflammatory cytokines are involved in the regulation of bone metabolism.  
During the process of normal bone resorption and formation, osteoclasts resorb bone 
within a bone remodeling unit (BMU) and osteoblasts then migrate to the site. The 
process of bone remodeling is mediated by signaling that occurs between stromal cell 
derived osteoblasts and osteoclasts which originate from a mesenchymal lineage.  For 
instance, osteoblasts express RANKL which promotes osteoclast differentiation and bone 
resorption.  The receptor for RANKL, RANK, is expressed on pre-osteoclasts and the 
RANKL-RANK interaction can promote pre-osteoclasts to differentiate into mature, bone 
resorbing cells.  In addition to RANKL, osteoblasts also secret a protein called OPG 
which acts as a decoy receptor for RANKL (86) and interferes with RANKL/RANK 
interaction therefore repressing osteoclastogenesis (86).  Hence the ratio of  RANKL to 
OPG is of importance in the regulation of bone resorption during normal remodeling and 
during states of chronic inflammation (i.e., ovarian hormone deficiency, and 
periodontitis, RA and ageing) (87, 88).  Similarly, OPG-deficient mice exhibit an 
osteoporotic phenotype due to the inability to suppress RANKL and osteoclastogenesis 
(89).   
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The mechanism responsible for the up-regulation of RANKL in response to 
inflammation may be explained in part by its relation to TNF-α.  TNF-α is a pleiotropic 
cytokine that induces cellular proliferation, production of inflammatory mediators, and 
cell death (90).  TNF-α exerts its biological actions by interacting with two membrane 
receptors: TNFR1, activated by the soluble TNF-  and TNFR2, activated by membrane-
bound TNF-α.  TNFR2 exclusively activates pro-inflammatory pathways, but does not 
induce apoptosis (91).  TNF-α has also been observed to stimulate the production of other 
inflammatory cytokines, such as RANKL and IL-1, which can enhance osteoclast 
differentiation (92, 93).  Furthermore it should also be noted that TNF-α has been shown 
to impact osteoblasts by inhibiting the maturation of pre-osteoblast cells (94), decreasing 
osteoblast activity (35) and stimulating osteoblast apoptosis (10).  Elevated TNF-α by 
peripheral blood monocytes has been positively correlated with bone resorption and 
vertebral bone loss in healthy pre- and post-menopausal women (95).  Increasing 
evidence suggests that the role of pro-inflammatory cytokines in respect to skeletal health 
is critical and has provided novel insight into their specific action on bone metabolism. 
Another family of cytokines that have been observed to have an impact on bone 
metabolism is the interleukins (IL).  Wei et al., (93) established that IL-1 is a potent 
stimulator of bone resorption and exerts this effect by enhancing stromal cell expression 
of RANKL.  Elevated IL-1  has been linked to the acceleration of bone loss as seen in 
idiopathic and postmenopausal osteoporosis (96).  Likewise, IL-6 is also involved in bone 
pathophysiology by promoting the differentiation and activation of osteoclasts (97).  
Recently, a longitudinal study documented  a strong negative correlation between 
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circulating IL-6 and total body BMD in elderly men and women suggesting an important 
role of IL-6 in age-related bone loss (98).   
Inflammation plays a significant role in atherosclerosis, the most common form of 
CVD.  The development of atherosclerosis is believed to be initiated by vascular injury or 
stress which may elicit an immune response, but in some cases may be initiated by 
persistent elevation of pro-inflammatory mediators (99).  In response to these factors, 
endothelial cells express adhesion molecules (e.g., intracellular adhesion molecule or 
ICAM-1 or vascular adhesion molecule or VCAM-1) that attract monocytes and 
subsequently other immune cell populations to the site (99).  Monocytes interact with the 
endothelium by the chemoattractant proteins (e.g. monocyte chemotactic protein-1 or 
MCP-1) and are translocated into the intima where they differentiate into macrophages 
(99). These macrophages may secrete inflammatory cytokines and take-up oxidized low 
density lipoprotein (LDL) and eventually differentiate into foam cells.  Foam cells will 
continue to secrete pro-inflammatory cytokines (i.e., TNF-α, IL-1β, and IL-8) (100), 
while simultaneously promoting the proliferation of smooth muscle cells.  Thus, these 
events highlight just a few of the key immunological aspects in the pathophysiology of 
atherosclerosis.  
Recently, RANKL and OPG have been recognized as having important roles on 
the vascular system, even though their initial function  was associated with the bone 
metabolism (101).  McGonigle et al., (102) observed that RANKL regulates endothelial 
cell proliferation, apoptosis, and signaling. OPG-deficient mice exhibit calcification of 
the aorta and renal arteries in addition to an osteoporotic phenotype (89).  Morony and 
colleagues (103) found that low density lipoprotein receptor knockout (ldlr-/-) mice 
 19
developed significant progression of atherosclerosis, but OPG administration reduced 
aortic osteocalcin, a marker of calcification.  Furthermore, stimulation of endothelial cells 
with TNF-α and IL-1 results in increased OPG is secretion that may represent the cells 
attempt to counter an increase in RANKL (104).  OPG is also beneficial by its ability to 
promote leukocyte adhesion to endothelial cells (105).  The impact that RANKL and 
OPG have on the vascular system may provide one potential link between the 
simultaneous bone loss and vascular pathology that are associated with inflammation.   
In addition to RANKL and OPG, substantial evidence supports a pro-atherogenic 
role for TNF-α and some of the interleukins.  TNFR1 expression  in the arterial wall, 
greatly contributes to early and late-stage atherosclerosis in mice by enhancing arterial 
wall chemokine and adhesion molecule expression, as well as by augmenting medial 
smooth muscle cell proliferation and migration (106).  Evidence suggests that TNF-α 
impairs endothelium-dependent and nitric oxide (NO)-mediated vasodilation in various 
vascular beds (e.g. mouse coronary arterioles) (107) and rat coronary arterioles (108).  
Expression of IL-1 and their receptors has been demonstrated in atheromatous tissue, and 
serum levels of IL-1-cytokines have been correlated with various aspects of 
cardiovascular disease and their outcome (109).  Furthermore, in stroke patients, elevated 
IL-6 at baseline seemed to be an independent predictor of further deterioration (110).  In 
both men and women serum IL-6 and TNF-α are significantly higher in patients with 
cardiovascular pathology and have been suggested to play a critical role in the 
progression of CVDs (111).   
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Animal Models of Chronic Inflammation, Bone Loss and Vascular Disease 
 To advance our understanding of the role of many of these inflammatory 
mediators in the development of osteoporosis and CVDs, it important to have an animal 
model that closely mimics the pathophysiology of human conditions.  Some of the more 
common models of chronic inflammation used in animals are the LPS-injection model 
(112), the collagen-induced arthritis model (113), and the colitis model (114, 115).  
Although all of these models have been shown to activate the immune response by up-
regulating inflammatory mediators, they were not ideal to examine the simultaneous 
development of skeletal and vascular pathology.  Confounding factors such as the stress 
of chronic handling with injection models, lack of weight-bearing on an inflamed foot 
pad in collagen-induced arthritis models, or alterations in nutrient absorption associated 
with colitis make these models less than ideal.   
Preferably, an animal model used to study chronic inflammation-induced bone loss 
and vascular pathology would induce a low-grade inflammatory response without 
significantly altering weight gain and normal animal behavior (i.e., physical activity, food 
intake, and grooming).  Our laboratory developed an animal model to study the effects of 
a low grade chronic inflammatory state on bone mass and metabolism that involved the 
use of a slow release pellet containing LPS (21).  In the initial study, adult 3-month old 
male Sprague Dawley rats were surgically implanted with LPS or placebo pellets 
designed to deliver 0.0, 3.3 or 33.3 μg LPS/day for 90 days (21).  The doses were based 
on the previous work of Jarvelainen et al., (116) in which LPS delivered via an osmotic 
pump for 4 weeks up-regulated hepatic TNF-α , IL-1β, IL-10, IL-4, and TGF- β, without 
inducing tolerance or significant weight loss.  In this study, both doses of LPS induced a 
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significant decrease in femoral BMD compared to the controls (21).  Histological cross-
sections of the myocardium indicated the inflammation not only induced changes in bone 
mass, but also  produced small vessel disease characterized by fibrosis surrounding the 
arterioles and a roughened intimal border within the intramural vessels (21, 22).  At the 
end of the 90 day study period, inflammatory mediators, cyclooxygenase (COX)-2, TNF-
α , and IL-1β, were up-regulated in the bone and myocardium which suggested this novel 
model  may provide an acceptable means of studying  inflammation-induced bone and 
cardiovascular pathology (21, 22).  In a subsequent study, eight-week old C57BL/6 
female mice were used to establish the dose of LPS that would induce similar bone loss 
and vascular disease in the mouse, and then to determine if soy-isoflavones could 
attenuate this response (24).  In this study it was determined that 1.33 μg LPS per day 
(~0.1 mg of LPS/kg/d) produced the greatest decrease in lymphocytes and increase in 
neutrophils, and decreased trabecular bone volume (BV/TV) and number (TbN), and 
increased separation (TbSp).  Moreover, TNF-α was up-regulated in the endothelium of 
small myocardial arteries and metaphyseal region of the bone, however soy isoflavones 
were able to attenuate this response (24).  Taken together, these studies suggest that this 
model provides a system to study how low level inflammation induces simultaneous 
development of bone loss and vascular disease and to explore potential interventions.   
 
Pharmacological Treatment Options for Osteoporosis and CVD 
A number of different drug therapies are available for the treatment of 
osteoporosis and CVDs that generally offer specific relief for one or the other conditions 
depending on the patient’s gender, lifestyle, and co-morbidities.  Most of the available 
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therapies for osteoporosis target either bone resorption or formation, and thus exert 
suppression on the loss of bone or stimulate new bone formation. 
The most commonly prescribed therapies for osteoporosis for osteoporosis have 
anti-resorptive properties.  Bisphosphonates (i.e. alendronate and risedronate) are the 
most commonly prescribed pharmacological treatment for osteoporosis (117).  Silverman 
et al.,  (117) demonstrated that patients receiving risedronate have lower rates of hip and 
nonvertebral fractures during their first year of therapy than patients receiving 
alendronate.  Oral bisphosphonates are relatively poorly absorbed and are associated with 
esophagitis, which make them poorly tolerated.  Due to these gastrointestinal issues, strict 
adherence to therapeutic protocols must be followed (e.g., drugs must be taken first thing 
in the morning, consume no other food or medications and take with a full glass of tap 
water).  Intravenous bisphosphonates are available, however, these potent anti-resorptive 
agents have been associated with increased incidence of osteonecrosis of the jaw (118).  
In addition to bisphosphonates, other anti-resorptive treatment options include calcitonin 
and hormone replacement therapy (HRT).  Calcitonin has been shown to decrease the 
loss of bone in the spine, but is by far the least potent of all of the anti-resorptive 
treatment options (119).  HRT remains a reasonable option for the prevention of 
osteoporosis, but is not recommended unless there are other indications for use (120).   
Another more recently FDA-approved drug available for the treatment of 
osteoporosis is teriparatide or intermittent PTH therapy.  Teriparatide (i.e. recombinant 
PTH peptide 1-34) is the only anabolic agent that can reverse bone loss in patients with 
established osteoporosis, and is administered by injection once a day in the thigh or 
abdomen (121).  In most cases, teriparatide is approved for treatment when 
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bisphosphonates have failed, and should be avoided in the young and in patients with 
previous radiation therapy and Paget’s disease (122).  Intermittent PTH has been 
demonstrated to increase bone mass and reduce vertebral and nonvertebral fractures, and 
has been approved for use in the US and Europe (122).  The most common side-effects of 
teriparatide are dizziness and leg cramps and elevations of blood calcium and urinary 
calcium can occur.  To date, the safety and benefits of teriparatide have not been 
evaluated beyond two years, so treatment for longer than two years is not recommended.    
Treatment of cardiovascular disease is dependent on the specific form of the 
disease, but is usually combined with lifestyle behavior modification (e.g. weight loss, 
altered nutrition, physical activity).  Patients at risk for or diagnosed with atherosclerosis 
may be on medications such as cholesterol lowering statins, blood pressure lowering 
drugs, or anti-platelet or anticoagulant drugs.  Over 11 million Americans are estimated 
to be on statin therapy which act by inhibiting HMG-CoA reductase, an essential enzyme 
in mevalonate formation and cholesterol biosynthesis (25).  In the late 1990’s, evidence 
emerged that statins may also have anti-inflammatory properties (29).  In 1999, Mundy 
and colleagues (29) reported that of the more than 30,000 compounds screened, 
lovastatin, stimulated BMP-2, a potent regulator of osteoblast differentiation and activity.  
This finding was significant due to the fact that most FDA-approved drugs for the 
treatment of osteoporosis have anti-resorptive properties, but that lovastatin could 
potentially stimulate bone formation.  The findings by Mundy and colleagues led other 
investigators to evaluate the relationship between statins, BMD, and fracture.  Chung and 
et al., (123) found that patients (n=69) on 3 commonly prescribed statins (i.e. lovastatin, 
pravastatin and simvastatin) for at least 15 months had increased BMD compared to the 
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control group after adjustment for age and body mass index.  These data suggest that 
HMG-CoA reductase inhibitors may increase femoral BMD in males.  Similar results 
have also been demonstrated in elderly women with increased hip BMD and reduced 
fracture risk (124).  Given that these initial studies demonstrated a positive association 
between statin use and BMD, other studies followed in attempt to identify the mechanism 
by which statins exert these beneficial skeletal effects. 
 These observational studies suggest a connection between statin therapy and bone 
metabolism; however, the effects of statins on bone resorption and mineralization remain 
unknown.  Tikiz et al., (125) observed that after three months of simvastatin treatment, 
postmenopausal women had increased serum markers of bone formation (i.e. ALP and 
osteocalcin) and a negative correlation was demonstrated between TNF-α and these bone 
markers.  These findings suggested that the anti-inflammatory effects of simvastatin may 
be involved in the bone remodeling process. While statins seemed to benefit bone 
forming osteoblast activity, they were also shown to have a substantial effect on 
osteoclasts activity via the inhibition of isoprenylated protein production, which are 
needed for osteoclast activity (28).  These data suggest that statins may have potent anti-
inflammatory effects and are both anti-resorptive and anabolic in terms of bone 
metabolism. 
 Although the mechanism by which statins reduce the risk of CVDs is associated 
with the inhibition of the rate-limiting enzyme, HMG-CoA reductase, in cholesterol 
synthesis, recent research suggests statin’s anti-inflammatory properties are contributing 
to the lower incidence of CVDs.  Studies (110, 126, 127) have shown that serum C-
reactive protein (CRP) is highly correlated with CVDs and patients receiving statin 
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therapy have lower serum CRP compared to controls.  Statins have also been shown to 
suppress the monocyte secretion of pro-inflammatory cytokines, such as IL-1β, IL-6, and 
IL-8 (128-130).  Wolfrum et al., (131) demonstrated that statins confer their beneficial 
effects by modulating endothelium-derived NO bioactivity, which attenuates endothelial 
dysfunction and atherosclerotic disease progression.  Recent studies recognize 
simvastatin’s role as an anti-inflammatory agent on human peripheral blood monocyte-
macrophages, including up-regulation of the atheroprotective factor Kruppel-like factor 2 
(KLF-2).  This observation may explain in part statins’ ability to reduce inflammation in 
the vessel wall (132).   
 
Natural Treatment Options for Osteoporosis and CVD 
 
Although there are therapeutic agents available for treatment of the individual 
symptoms associated with CVDs and osteoporosis, many of these treatments are 
associated with undesirable side-effects.  Additionally, some patients may prefer a more 
natural treatment option.  To date there has been no therapeutic agent developed to target 
both osteoporosis and CVD occurring simultaneously and as a result many patients end 
up taking multiple medications.  A number of dietary supplements are known to have 
anti-inflammatory effects such as fish oils and phytochemicals found in fruits and 
vegetables.  Specifically in fruits and vegetables, compounds known as polyphenols are 
one of the components that may be responsible for the anti-inflammatory qualities of the 
plant-based foods.   
Polyphenols are a group of chemical substances found in plants, characterized by 
the presence of more than one phenol unit or building block per molecule, this unique 
chemical structure allows for these compounds to have potent anti-inflammatory 
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capacity.  Dietary polyphenols have the ability to scavenge free-radicals, which can have 
devastating effects on our biological systems.  For example, rutin, a glycoside of 
quercetin found mainly in onions but is also in plums, was able to prevent OVX-induced 
bone loss in rats and reduced urinary excretion of deoxypyridinoline (Dpd) and calciuria 
(133).  EGCG, one of the primary polyphenols in green tea, appears to induce 
osteoclastic cell death (41), and enhance osteoblastic differentiation by up-regulating 
runt-related transcription factor 2 (Runx2) and osterix gene expression (134).  
Resveratrol, commonly found in red wines, has been shown to enhance the proliferation 
and differentiation of human osteoblastic cells (135).  Both the consumption of tea (136) 
and red wine (137) are associated with a lower the risk of myocardial infarction in both 
case-control and cohort studies.  Chlorogenic acid is the most abundant polyphenol in 
dried plum, and in vitro has been shown to have positive effects on oxidative stress, 
which is responsible for deterioration of cardiovascular health (138).  Polyphenols have 
also been shown to improve endothelial dysfunction, which is an early event in 
atherosclerosis (139, 140).  Endothelial-dependant vasorelaxing activity has been 
demonstrated with wine anthocyanins (141) soy isoflavones (142) and quercetin (143) in 
animal studies.  Droke et al., (24) found that dietary supplementation with soy 
isoflavones in mice protected against the inflammation-induced effects on skeletal 
microarchitecture and reduced TNF-α protein in endothelium of small myocardial arteries 
and arterioles (24).  Therefore dietary polyphenolic compounds appear to protect against 
inflammation-induced osteoporosis and CVDs and may offer consumers an easily 
obtainable treatment with fewer side-effects.   
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Dried plums are known to have a very high content of polyphenolic compounds.  
These characteristics make this fruit an ideal candidate for the possible reversal of the 
pathology observed in osteoporosis and CVDs.  Arjmandi et al., (33) were the first to 
report that 25% dried plum (w/w) was able to prevent the ovariectomy-induced bone loss, 
and enhance serum IGF-1 in rats.  Subsequently, a clinical study with postmenopausal 
women designed to assess the effect of dried plum supplementation (compared to dried 
apples) on bone biochemical markers revealed that women consuming the dried plums 
(i.e. ~100 g/d) experienced an increase in serum IGF-1 and BAP (144).  Dried plum, in 
doses as low as 5% of total diet, has been shown to reverse the loss of tibial and femoral 
bone density in ovariectomized rats (32).  Further studies have led to the conclusion that 
some component(s) of dried plum are able to suppress bone resorption (145) and also 
increase bone formation (32).  In a male model of osteoporosis, orchidectomized rats 
were fed dried plum (5%, 15%, or 25%), the 15% dried plum diet had an increased 
femoral and lumbar spine BMD, and the 25% dried plum diet has completely prevented 
the decrease in BMD, this trend was also observed in microarchitectural parameters of 
the spine (34).  Through the use of orchidectomized rats, conclusions were drawn that 
dried plum was able to restore bone similar to that of the pharmacological treatment PTH, 
however it seems likely that a different mechanism is involved (146).  Bu et al., (35) 
showed that dried plum’s polypehnols were able to increase phosphatase ALP activity 
under normal and inflammatory conditions, and increased the gene expression of Runx2, 
Osterix, IGF-1 and nodule formation, while simultaneously down-regulating RANKL 
expression.  Bu and colleagues (36) also determined dried plum’s polyphenols 
significantly reduced nitrite production in LPS treated pre-osteoclast and osteoclast cells, 
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and decreased TRAP positive cells (36).  These in vitro studies suggest that the whole 
fruit dried plum is able to exert anabolic and anti-resorptive effects on bone by the action 
of its polyphenols.  In terms of cardiovascular system, dried plum has also been shown to 
suppress OVX-induced hypercholesteremia in rats by decreasing serum total cholesterol, 
triacylgycerides, and non-HDL cholesterol (38).  Since it is known that dried plums 
contain such a high amount of polyphenols and based on in vitro studies, it is reasonable 
to attribute the skeletal and vascular protective properties of dried plum in part to their 
phenolic compounds. 
 In short, osteoporosis and CVDs are a major health concern in the U.S as well as 
many other developed countries.  With the demographic shift towards an older society in 
such countries, these trends will only increase.  Accumulating evidence from clinical and 
pre-clinical studies identified the pathophysiology of osteoporosis and CVD, and 
established a working premise that inflammation may play a central role in the 
development and progression of each condition (21).  Our previous work suggests that 
dried plum’s polyphenols may be an ideal candidate to explore as a single strategy for the 
treatment of concurrent CVDs and osteoporosis due to their potent anti-inflammatory 
abilities.  Therefore the purpose of this study is to assess the effects of dried plum and its 
polyphenols on low grade chronic inflammation-induced changes in bone 
















Three-month old female C57BL/6 mice (n=192) were obtained (Jackson Labs, 
Bar Harbor, ME) and housed in environmentally controlled conditions.  Following a 
seven day acclimation period, animals were randomly assigned to treatment groups 
(Table 1) and were surgically implanted with either a placebo (n=36) or LPS pellet 
(Innovative Research of America, Sarasota, FL) designed to deliver 0.1 mg LPS/kg bw 
/day (n=156).  Treatments included AIN-93M control diet (147), control diet with low 
(LDP) or high (HDP) dose dried plum added (low dose = 5% or high dose = 25%, w/w), 
control diet with comparable dose of polyphenolic compounds as low (LPP) and high 
(HPP) dose dried plum, or simvastatin (25 mg/kg diet) as a positive control.  All animals 
were maintained on the control diet for an initial 4 week period to allow the bone and 
vascular pathology to develop in the animals receiving LPS.  At the end of 4 weeks, two 
groups of mice (i.e. a placebo and an LPS group) were sacrificed and data were collected 
for baseline characterization of bone mass and microarchitecture, gene expression from 
femoral RNA, and histological evaluation of the myocardium and aorta.  The remaining 
animals were immediately started on their respective treatments fortreatment period food 
intake was monitored and animals were match fed to the group consuming the least 
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amount of diet (i.e. adjusted once a week).  All animals had free access to  deionized 
water and were weighed weekly.   
At necropsy (i.e., baseline, 2 weeks, or 6 weeks), mice were anesthetized with an 
intramuscular injection of ketamine/xylazine cocktail 100.0/10.0 mg/kg bw and 
exsanguinated by the carotid artery.  Bone (i.e. femurs and tibias), heart, aorta and liver 
specimens were harvested for future analyses.  The femurs and tibias were cleaned of all 
adhering soft tissue and either snap frozen for RNA extraction or fixed in 10% neutral 
buffered formalin for μCT analyses.  The heart and aorta were removed, fixed in10% 
neutral buffered formalin for histological examination.  Portions of the liver were snap 
frozen for protein analyses, while the remainder of the liver was fixed in 10% neutral 
buffered formalin.  All procedures were strictly adhered to the guidelines set for by the 
University of Oklahoma Health Sciences Center IACUC. 
 
Implantation of Pellets 
Time release pellets (Innovative Research of America, Sarasota, FL) were 
designed to deliver 0 or 0.1 mg LPS/kg bw /d for 90 days.  The doses were selected based 
on the results from our previous study in which bone loss and vascular pathology 
developed (21, 22, 46).  Surgical placement of the pellet required animals to be 
anesthetized with an intramuscular injection of ketamine/xylazine cocktail 10.0 mg/kg 
and the dorsal back of the mice was shaved.  A small incision was made (~2 cm from the 
site of placement) and forceps were used to tunnel to the interscapular region where the 




Extraction of Polyphenols from Dried Plum Powder 
 
 Polyphenols were extracted from 10 g batches of dried plum powder.  This was 
accomplished by adding 100 mL of 80% ethanol to dried plum powder in an Erlenmeyer 
flask and sonicating the mixture in an ice cold (~4°C) water bath for 20 min, while being 
exposed to a continuous flow of N2 gas to ensure polyphenol integrity.  Once sonication 
was completed, the liquid was vacuum filtered using a chilled Buchner funnel lined with 
filter paper (8μm particle size).  The flask was rinsed twice with 50 mL of 100% ethanol.  
The remaining dried plum powder was scraped from the filter paper and the extraction 
procedure repeated.  Upon the completion of the extraction, approximately 400 mL of 
ethanol-extracted polyphenols were transferred to a round-bottom flask and the volume 
reduced to about 40% (~10 mL remaining) by roto-evaporation at 35°C and 60 rpm.  The 
extract was then collected and stored in -80°C before being freeze dried (VirTis, 
Gardiner, NY).  
 
Total Polyphenolic Analysis and Diet Formulation 
To analyze the total phenolic content of the extract was determined by the Folin-
Ciocalteu assay.  First, 15 mL of ethanol was added to 150 mg of powder extract, 
sonicated for 30 min, and then filtered.  About 1 mL of filtered extract was added to 100 
mL volumetric flask with 60-70% HPLC grade water and 5 mL of Folin-Ciocalteu’s 
phenol reagent was added and mixed.  After two hours the absorption was measured at 
760 nm.  The same solution without extract was used as a blank.  Calculation of the 
percent of total phenolics was determined based on a standard curve.  The polyphenolic 
content of the diets (i.e. low and high) were based on the amount of  polyphenolic 
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compounds provided in the 5% dried plum and 25% (w/w) dried plum diet.  Diets were 
formulated to be isocaloric and have similar carbohydrate, fat, protein, calcium and 
phosphorous content (Table 2).   
 
BMD Assessment Using DXA 
 Excised tibias were used for DXA scans (GE Medical Systems,LunarPIXI, 
Madison, WI) performed on specimens harvested at baseline, 2 and 6 weeks post dietary 
treatments to determine the bone mineral area (BMA), bone mineral content (BMC), and 
bone mineral density (BMD).  All DXA scans were performed using PIXImus Series 
Software version 1.4x. 
 
Microcomputed Tomography Analyses 
The tibia was scanned using μCT (MicroCT40, SCANCO Medical, Switzerland) 
to assess trabecular and cortical bone microarchitecture.  The proximal tibia was the site 
of trabecular bone analyses while the tibial mid-diaphysis was analyzed for cortical bone 
parameters.  Tibia scans were performed at high resolution (2048 x 2048 pixels).  The 
proximal tibia metaphysis was analyzed by acquiring 175 slices and evaluating 100 slices 
(600 μm) in the volume of interest (VOI).  Semi-automated contours were placed starting 
5 slices (30 μm) distal to the growth plate to assess secondary spongiosa within the VOI.  
Trabecular bone volume expressed per unit of total volume (BV/TV), trabecular number 
(TbN), separation (TbSp), and thickness (TbTh), were determined and connectivity 
density (ConnDens) and structural model index (SMI) were calculated. The midshaft of 
the tibia was evaluated by acquiring 27 slices at the midpoint, and analyzing 20 slices 
(120 μm).  Cortical porosity, thickness, area and medullary area were assessed to 
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determine the alterations in cortical bone associated with inflammation and the dietary 
treatments. 
 
Finite Element Analysis 
Images acquired with μCT allowed for further evaluation of the biomechanical 
parameters on trabecular bone structures using finite element analysis (FE) software 
(SCANCO Medical).  A micromechanical FE model was constructed by converting bone 
voxels from the VOI into 8-node brick elements (148).  The elements in this FE model 
have been shown to have a linear, elastic and isotropic material properties described by a 
Poisson’s ratio of 0.3 and a Young’s modulus of 10 GPa (149).  Compression testing was 
simulated on the reconstructed 3-D images of the proximal tibia, total force and size-
independent stiffness was determined (150).   
 
RNA Extraction and Quantitative Real-Time PCR 
Whole femurs were pulverized (Spex 6770 freezer mill) and homogenized-bone 
powder was immediately placed in 1 mL of Trizol Reagent (Life Technology, Rockville, 
MD, USA).  Trizol and bone were centrifuged at 4°C for ~5 min at 12,000 x g.  The top 
phase was then removed and transferred to a clean, RNase-free microfuge tube and 
allowed to incubate at ~25°C for 5 min.  Next, 200 μL of chloroform was added and 
vigorously shaken for 15 sec.  The mixture was allowed to incubate for 3 min followed 
by centrifugation at 12,000 x g for 10 min at 4°C.  The clear aqueous phase was then 
transferred to a clean tube and 250 μL isopropanol and 250 μL high salt solution (1.2 M 
NaCl and 0.8 M Na3C3H5O(COO)3) were added and allowed to precipitate on ice for 30 
min.  To pellet the RNA, the solution was centrifuged at 4°C for 15 min at 12,000 x g and 
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the RNA pellet was observed.  The supernatant was removed, and the pellet was washed 
with 75% ethanol and centrifuged again at 7,500 x g for 5 min at 4°C.  The RNA pellet 
was resuspended in 20 μL of diethylpyrocarbonate (DEPC) H2O.  To determine quantity 
and quality of RNA, the concentration and A260/A280 ratio was obtained using a Nanodrop 
Spetrophotometer (Rockland, DE).   
Quantitative real time PCR was performed using 2 μg of total RNA pre-treated 
with DNase I and subjected to reverse-transcription (Superscript II, Invitrogen, Carlsbad, 
CA).  Fifty ng of cDNA were used for each qRT-PCR reaction and all reactions were 
assayed in duplicate using SYBR green chemistry (Roche, Penzberg, Germany) on the 
Applied Biosystems 7300 Real Time PCR (Foster City, CA).  The primer sequences for 
genes of interest were designed based on Genebank database or published species-
specific sequences (Table 3).  The criteria used for primer design/validation is the 
amplicon must span an intron, template titration must have an efficiency slope of -3.3, 
and demonstrate the formation of a single dissociation curve.  All qRT PCR results were 
evaluated by the comparative cycle number at threshold (CT) method using hypoxanthine 
guanine phosphoribosyltransferase 1 (HPRT1) as the invariant control.   
 
Histology 
Cross-sections of the aorta and heart were paraffin-embedded and cut into 5-μm 
sections.  Sections were then stained with hemotoxylin and eosin (H&E) for analysis of 
cellular and tissue pathology.  All slides were graded using a scoring system by the study 
pathologist.  The arteries and arterioles were scored based on the degree of narrowing:  0, 
no observed narrowing of vessel through 3, severe narrowing of vessel.  Within the 
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myocardium, inflammatory infiltrate such as lymphocytes and polymorphonuclear cells 
(PMN) along with mast cells were graded as such: 0, no visible infiltration through 3, 
severe infiltration.  The aorta scores were totaled from three parameters of thickening of 
the wall (0-3), thinning of the wall (0-3) and artheromatous plaque (0-3), so the highest 
possible score is 9.  Infarction was graded as either 0, no observed event or 1, in the event 
of a myocardial infarction. 
 
Statistical Analyses 
Descriptive statistics were calculated for all variables and included means and 
standard error.  Data were analyzed using ANOVA (SAS Version 9.1; SAS Institute, 
Cary NC).  Bone and vascular structure and calcification were investigated through linear 
correlation coefficients.  Categorical data derived from the pathology scoring were 
compared using Chi-squared test followed by Fisher’s Exact Test to confirm significance. 
Values were expressed as means ± standard error (SE), and p<0.05 was considered to be 
statistically significant for all analyses. 
Table 1.  Treatment Groups 
 
 
Baseline 2 weeks 6 weeks 
Placebo + Control Diet Placebo + Control Diet Placebo + Control Diet 
LPS + Control Diet LPS + Control Diet LPS + Control Diet 
  LPS + High Dose Dried Plum (HDP) LPS + High Dose Dried Plum (HDP) 
  LPS + Low Dose Dried Plum (LDP) LPS + Low Dose Dried Plum (LDP) 
  LPS + High Dose Polyphenols (HPP) LPS + High Dose Polyphenols (HPP) 
  LPS + Low Dose Polyphenols (LPP) LPS + Low Dose Polyphenols (LPP) 
  LPS + Statin LPS + Statin 
Slow release pellets delivered 0 (Placebo) or 0.1 mg LPS/kg bw/d (LPS). Baseline animals received only AIN-93M (control) diet.  
Dietary treatments were: control diet, control diet with low (LDP) or high (HDP) dose dried plum added (low = 5% or high = 25%, 
w/w), control diet with comparable dose of polyphenolic compounds as low (LPP) and high (HPP) dose dried plum, or simvastatin 
(Statin) as a positive control (25 mg/kg diet).  Dietary treatments started after the baseline sacrifice (4 weeks post pellet implantation) 
and were maintained for 2 or 6 weeks.  
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Table 2.  Formulation of Diet  
 
Ingredients Control LDP HDP LPP HPP 
 g/ kg Diet 
Dried Plum ₋ 50 250 ₋ ₋
Polyphenol Extract ₋ ₋ ₋ 32.1 160.7 
Carbohydrate      
    Cornstarch 466 425.7 265.7 439.4 334 
    Sucrose 100 100 100 100 100 
    Dextrinized Cornstarch 155 155 155 155 155 
Protein      
    Casein 140 138.5 132.5 138.9 134.6 
Fat      
    Soybean Oil 40 39.75 38.75 39.8 38.9 
Fiber      
    Cellulose 50 45.5 55 50 50 
      
Vitamin Mix 10 10 10 10 10 
Mineral Mix (Ca-P Def) 13.4 13.4 13.4 13.4 13.4 
Sucrose 2.2 2.6 4.6 2.4 4.0 
Calcium Carbonate 12.5 12.4 12.1 12.4 12 
Sodium Phosphate, 
    Monobasic 
5.6 5.5 4.8 5.6 5.2 
Potassium Phosphate, 
    Monobasic 
2.4 2.4 2.4 2.4 2.4 
Choline Bitartrate 2.5 2.5 2.5 2.5 2.5 
L-cysteine 1.8 1.8 1.8 1.8 1.8 
Tert-butylhydroquinone 0.008 0.008 0.008 0.008 0.008 
      
Dietary treatments were: control diet, control diet with low (LDP) or high (HDP) dose 
dried plum added (low = 5% or high = 25%, w/w), control diet with comparable dose of 
polyphenolic compounds as low (LPP) and high (HPP) dose dried plum, or simvastatin 
(Statin) as a positive control (25 mg/kg diet).
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Table 3.  List of Primer Sequences Used for Real Time-PCR 
Symbol Name Accession # Sequence 
 
ALP Alkaline phosphatase  QF 5'- GGT ATG GGC GTC TCC ACA GT -3' 
NM_007431.2 QR 5'- GCC CGT GTT GTG GTG TAG CT -3' 
HPRT1 Hypoxanthine guanine phosphoribosyltransferase 1  QF 5'- GCC TAA GAT GAG CGC AAG TTG -3' 
NM_013556.2 QR 5'- TAC TAG GCA GAT GGC CAC AGG -3' 
IGF-1 Insulin-like growth factor 1  QF 5'- CCA CAC TGA CAT GCC CAA GA -3' 
NM_184052.2 QR 5'- CTC CTT TGC AGC TTC GTT TTC T -3' 
IL-6 Interleukin 6  QF 5'- GAG GAT ACC ACT CCC AAC AGA CC -3' 
NM_031168.1 QR 5'- AAG TGC ATC ATC GTT GTT CAT ACA -3' 
IL-10 Interleukin 10  QF 5'- GGT TGC CAA GCC TTA TCG GA -3' 
NM_010548.1 QR 5'- ACC TGC TCC ACT GCC TTG CT -3' 
OPG Osteoprotegerin  QF 5'- TCC TGG CAC CTA CCT AAA ACA GCA -3' 
NM_008764.3 QR 5'- ACA CTG GGC TGC AAT ACA CA -3' 
RANKL Receptor activator for nuclear factor κ B ligand  QF 5'- CTG ATG AAA GGA GGG AGC AC -3' 
NM_011613.3 QR 5'- GAA GGG TTG GAC ACC TGA ATG -3' 
TNF-α Tumor necrosis factor-alpha  QF 5'- CTG AGG TCA ATC TGC CCA AGT AC -3' 
NM_013693.2 QR 5'- CCT CAC AGA GCA ATG ACT CCA AAG -3' 
TRAP Tartrate resistant acid phosphatase  QF 5'- CTG CAC AGA TTG CAT ACT CTA AGA TCT-3' 
NM_007388.3 QR 5'- TTT GAA GCG CAA ACG GTA GTA A -3' 
The criteria used for primer design/validation is the amplicon must span an intron, template titration must have an efficiency 
slope of -3.3, and demonstrate the formation of a single dissociation curve. 
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Figure 1.  Experimental design 
 
 
Placebo or LPS pellets were implanted on day 0 and baseline sacrifice was performed 4 weeks later on one Placebo and one LPS 
group. During the first 4 weeks all  animals received  AIN-93M (control) diet.  Dietary treatments were: control diet, control diet with 
low (LDP) or high (HDP) dose dried plum added (low = 5% or high = 25%, w/w), control diet with comparable dose of polyphenolic 
compounds as low (LPP) and high (HPP) dose dried plum, or simvastatin (Statin) as a positive control (25 mg/kg diet).  Dietary 







Bone Mass and Densitometry  
 To determine the alterations in bone density in response to LPS and treatment, 
excised tibias were scanned using dual-energy X-ray absorptiometry.  There was no 
significant difference in tibial BMC, BMA (Table 4), or BMD (Figure 2) between the 
placebo or LPS pellet group’s tibia on control diet at baseline.  After 2 and 6 weeks on 
dietary treatments, no differences were observed in tibial BMC, BMA (Table 4), or BMD 
(Figure 2) in any of the treatment groups or between the placebos versus LPS treated 
groups on control diet.  These findings suggest that no alterations occurred in tibial bone 
mass and density in response to LPS or treatment over the course of the study.  
 
Proximal Tibia Trabecular and Cortical Bone Microarchitecture 
 Analysis of trabecular bone of the proximal tibia at baseline revealed that though 
there were no alterations in BV/TV (Figure 3A), but there was a significant increase in 
trabecular separation (TbSp) in the mice exposed to LPS compared to the placebo group 
(Figure 3D).  No other alterations in trabecular bone morphometric parameters at the 
proximal tibia were observed at baseline, including trabecular number (TbN) and 
trabecular thickness (TbTh) (Figure 3B and 3C).  Trabecular bone connectivity density, 
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which indicates the number of trabecular connections in a given volume of interest, 
tended to be lower in the LPS group compared to placebo group (Table 5).  As expected, 
LPS did not significantly alter any of the cortical parameters at the tibial midshaft at 
baseline (Table 6).  At 2 weeks and 6 weeks no trabecular (Figures 4 & 5) or cortical 
bone parameters (Table 7) were altered by LPS or dietary treatments. 
 
Biomechanical Properties of Trabecular Bone 
 Due to the lack of an effect on trabecular bone microarchitecture, finite element 
analysis revealed that there were no differences in total force or size independent stiffness 
between groups at baseline or after 2 weeks and 6 weeks of treatments (Table 8). 
 
Gene Expression of Whole Femurs 
 In contrast to our expectation, at baseline there were no statistically significant 
differences in gene expression of the pro-inflammatory mediators TNF-α and IL-6, or in 
the anti-inflammatory mediator IL-10 (Figure 6A-C).  There was also no observed 
difference (P<0.05) in genes associated with bone resorption including RANKL, OPG, 
TRAP, and the RANKL/OPG ratio (Figure 7A-D).  Likewise, at baseline there were no 
alterations in the bone ALP, which is an indicator of bone formation (Figure 8).  
Following two weeks of treatment, there continued to be no statistically 
significant differences in TNF-α, IL-6, and IL-10 gene expression in the femur of the 
LPS group compared to the placebo (Figure 9A-C). No alterations bewteen any of the 
treatment groups were observed in IL-6 or IL-10, but the high dose of dried plum 
polyphenols (HPP) did down-regulate (P<0.05) the relative gene expression of TNF-α, 
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compared to the placebo and LPS control groups (Figure 9A).  Expression of other target 
genes involved in bone resorption, RANKL, TRAP, OPG and the RANKL/OPG ratio 
were not statistically altered by the LPS compared to placebo, or within any of the 
treatment groups at 2 weeks (Figure 10A-D).  At two weeks post dietary treatment, ALP 
gene expression had not been significantly altered, by LPS or any of the treatment groups 
(Figure 11A).  IGF-1 gene expression was significantly decreased in the LPS cohort on 
control diet compared to the placebo group, however, none of the dietary treatments were 
able to increase IGF-1 expression (Figure 11B).  
After 6 weeks of treatment, there were no statistically significant differences 
observed in bone TNFα, IL-6, or IL-10 relative gene expression (Figure 12A-C).  
RANKL gene expression was significantly up-regulated by LPS in the group on the 
control diet compared to the placebo group (Figure 13A).  HPP and LDP down-regulated 
RANKL gene expression in mice with the LPS pellet similar to that of the mice 
implanted with the placebo pellet (Figure 13A).  However, there was no statistically 
significant difference in gene expression associated with bone resorption (Figure 13D) or 
bone formation (Figure 14) at six weeks.  
 Our positive control, simvastatin had no significant effect on any parameters 
tested other than IGF-1 at 2 weeks (Figure 11B) and RANKL at 6 weeks (Figure 13A).  
Statin therapy was able to down-regulate IGF-1 compared to placebo and LPS controls 
after 2 weeks on dietary treatment.  RANKL gene expression was also significantly 
lowered compared to LPS control group after 6 weeks of treatment.  Based on previous 
reports that statin drugs have anti-inflammatory and potential anabolic effects on bone, 
simvastain was included in the study designed as a positive control.  After 2 and 6 weeks 
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of statin treatment, animals exhibited no response in the expression of TNF-α, IL-6 or IL-
10 mRNA (Figure 9 and 13).  
 
Histological Evaluation of the Myocardium and Aorta 
Representative micrographs of the heart (Figure 15) and aorta (Figure 16) are 
shown.  After 2 weeks of treatment the LPS pellet had not altered narrowing of large or 
small artery or arterioles compared to the placebo group (Table 9).  Lymphocyte 
infiltration of the heart had significantly increased in the LPS control group compared to 
the placebo after 2 weeks dietary treatment, the high dose of dried plum and statin 
therapy were able to decrease this response (Table 10).  Mast cell and PMN infiltration 
frequency were not statistically altered by the LPS after 2 weeks of dietary treatment (6 
weeks after pellet implantation) (Table 10).  
At 6 weeks post dietary treatment (10 weeks after placebo or LPS pellet 
implantation), the LPS group on control diet had a significantly higher degree of large 
and small artery narrowing, however, all of the dietary treatments were able to reverse 
these vascular changes (Table 11).  All treatment groups with exception of the low dose 
of dried plum,were ble to decrease the f narrowing of large arterioles.  No treatments 
were able to impact the frequency of small arteriole narrowing (Table 11).  The LPS 
pellet increased the degree of lymphocyte infiltrate of the heart, and all of the treatments 
attenuated this cellular response to a similar degree (Table 12).  Although PMN 
infiltration was observed in 83% of the LPS treated heart specimens, this was not 
observed in any of the LPS groups on the dietary treatments (Table 12).  The LPS group 
on control diet had a statistically higher number of mast cells in the heart compared to 
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placebo and the high dose of dried plum (Table 12).  At 9 weeks post dietary treatments 
or control diets, no animals had an observed infarction (Table 12).  There were no 
statistical differences in aortas at 2 weeks post dietary treatment (Table 13).  After 6 
weeks of dietary treatment, the LPS had induced vascular changes leading to higher 
pathology scores in the aorta compared to the placebo control.  All treatments were able 
to reduce these negative effects on the aorta (Table 13). 
Table 4.  Bone Mineral Area (BMA) and Content (BMC) of the Tibia at Baseline and Following 2 and 6 Weeks of Dietary Treatments 
 
 
 Placebo LPS LPS/LPP LPS/HPP LPS/LDP LPS/HDP LPS/Statin 
Baseline       
BMA (cm2) 0.480 ± 0.01 0.470 ± 0.01     
BMC (g) 0.0242 ± 0.001 0.0238 ± 0.001     
2 weeks       
BMA (cm2) 0.456 ± 0.04 0.490 ± 0.01 0.502 ± 0.01 0.510 ± 0.01 0.511 ± 0.01 0.501 ± 0.01 0.488 ± 0.010 
BMC (g) 0.0267 ± 0.001 0.0263 ± 0.001 0.0273 ± 0.001 0.0285 ± 0.001 0.0284 ± 0.001 0.0276 ± 0.001 0.0263 ± 0.001 
6 weeks       
BMA (cm2) 0.512 ± 0.01 0.527 ± 0.01 0.512 ± 0.01 0.513 ± 0.01 0.520 ± 0.01 0.519 ± 0.01 0.499 ± 0.01 
BMC (g) 0.0289 ± 0.0007 0.0305 ± 0.001 0.0291 ± 0.001 0.0283 ± .001 0.0301 ± 0.001 0.0299 ± 0.001 0.0271 ± 0.001 
Slow release pellets delivered 0 (Placebo) or 0.1 mg LPS/kg bw/d (LPS). Baseline animals received only AIN-93M (control) diet.  Dietary treatments were: 
control diet, control diet with low (LPS/LDP) or high (LPS/HDP) dose dried plum added (low = 5% or high = 25%, w/w), control diet with comparable dose of 
polyphenolic compounds as low (LPS/LPP) and high (LPS/HPP) dose dried plum, or simvastatin (LPS/Statin) as a positive control (25 mg/kg diet). Dietary 
treatments started after the baseline sacrifice (4 weeks post pellet implantation) and were maintained for 2 or 6 weeks.  
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Table 5.  Tibia Trabecular Bone Microarchitectural Parameters at Baseline and Following 2 or 6 Weeks of Dietary Treatments  
 
 
 Placebo  LPS  LPS/LPP  LPS/HPP  LPS/LDP  LPS/HDP  LPS/Statin  
Baseline         
ConnDens   341.09 ± 23.2 276.92 ± 22.3      
SMI 1.39 ± 0.1 1.63 ± 0.1      
2 weeks        
ConnDens  304.28 ± 21.4 377.49 ± 25.9 281.13 ± 21.2 270.59 ± 31.3 293.00 ± 15.6 301.72 ± 27.9 349.17 ± 34.8 
SMI 1.24 ± 0.2 1.30 ± 0.1 1.28 ± 0.2 1.41 ± 0.1 1.34 ± 0.1 1.28 ± 0.2 1.22 ± 0.2 
6 weeks        
ConnDens  272.6 ± 32.6 274.4 ± 41.5 369.9 ± 93.4 248.3 ± 6.1 241.7 ± 32.7 281.6 ± 12.2 226.5 ± 18.6 
SMI 0.87±0.2 1.00 ± 0.2 0.85 ± 0.2 1.04 ± 0.2 0.92 ± 0.2 0.77 ± 0.2 0.94 ± 0.2 
Connectivity density (ConnDens) and structural model index (SMI) as assed by μCT.  Slow release pellets delivered 0 (Placebo) or 0.1 mg LPS/kg bw/d (LPS). 
Baseline animals received only AIN-93M (control) diet.  Dietary treatments were: control diet, control diet with low (LPS/LDP) or high (LPS/HDP) dose dried 
plum added (low = 5% or high = 25%, w/w), control diet with comparable dose of polyphenolic compounds as low (LPS/LPP) and high (LPS/HPP) dose dried 
plum, or simvastatin (LPS/Statin) as a positive control (25 mg/kg diet). Dietary treatments started after the baseline sacrifice (4 weeks post pellet implantation) 
and were maintained for 2 or 6 weeks.  
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Table 6.  Cortical Bone Morphometry at the Tibial Mid-diaphysis. 
 
 
 Placebo  LPS  
Baseline    
Cortical Thickness (mm)  0.239 ±0.001 0.241±0.01 
Cortical Area (mm2)  0.82 ±0.04  0.83 ±0.02  
Medullary Area (mm2)  0.0117 ±0.00 0.0109±0.00 
Porosity (%)  1.39 ±0.07                                   1.31 ±0.03 
Baseline animals had either placebo pellet (0.0 μg LPS/day) or an LPS pellet delivering 0.1 mg LPS/kg/d, and maintained on 
control diet for 4 weeks.   
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Table 7.  Cortical Bone Morphometry at the Tibial Mid-diaphysis After 2 or 6 Weeks of Dietary Treatments 
 
 
 Placebo  LPS  LPS/LPP  LPS/HPP  LPS/LDP  LPS/HDP  LPS/Statin  
2 weeks        
Cortical Thickness (mm)  0.236 ± 0.00  0.240 ± 0.01  0.257 ± 0.01  0.246 ± 0.01  0.248 ± 0.01 0.251 ± 0.01 0.243 ± 0.01  
Cortical Area (mm2)  0.815 ± 0.02 0.796 ± 0.03  0.914 ± 0.03  0.837 ± 0.03  0.865 ± 0.03  0.874 ± 0.04  0.860 ± 0.03  
Medullary Area (mm2)  1.071 ± 0.01  1.070 ± 0.07  1.190 ± 0.06  1.143 ± 0.09  1.219 ± 0.13  1.083±0.05  1.131 ± 0.02  
Porosity (%)  1.31 ± 0.04  1.36 ± 0.13 1.31± 0.07 1.36 ± 0.08  1.42 ± 0.14 1.25 ± 0.064 1.32 ± 0.08  
6 weeks        
Cortical Thickness (mm)  0.254 ± 0.01  0.259 ± 0.01  0.268 ± 0.00  0.246 ± 0.01  0.258 ± 0.01  0.256 ± 0.01  0.238 ± 0.01  
Cortical Area (mm2)  0.844 ± 0.05  0.935 ± 0.11  0.952 ± 0.08  0.804 ± 0.05  0.864 ± 0.07  0.939 ± 0.01  0.862 ± 0.04  
Medullary Area (mm2)  1.035 ± 0.10  1.060 ± 0.11  1.039 ± 0.11  1.062 ± 0.06  0.897 ± 0.07  1.29 ± 0.06  1.19 ± 0.14  
Porosity (%)  0.55 ± 0.02  0.53 ± 0.01  0.52 ± 0.01  0.57 ± 0.01  0.54 ± 0.02  0.51 ± 0.01  0.58 ± 0.02  
Slow release pellets delivered 0 (Placebo) or 0.1 mg LPS/kg bw/d (LPS).  Baseline animals received only AIN-93M (control) diet.  Dietary treatments were: 
control diet, control diet with low (LPS/LDP) or high (LPS/HDP) dose dried plum added (low = 5% or high = 25%, w/w), control diet with comparable dose of 
polyphenolic compounds as low (LPS/LPP) and high (LPS/HPP) dose dried plum, or simvastatin (LPS/Statin) as a positive control (25 mg/kg diet).  Dietary 
treatments started after the baseline sacrifice (4 weeks post pellet implantation) and were maintained for 2 or 6 weeks.  
 49
Table 8. Biomechanical Properties of the Tibia as Assessed by Finite Element (FE) Analysis at Baseline and Following 2 or 6 Week 
of Dietary Treatments 
 
 
 Placebo  LPS  LPS/LPP  LPS/HPP  LPS/LDP  LPS/HDP  LPS/Statin  
Baseline         




714.71 ±94.5 601.35 ±67.7      
2 weeks 
 
       




727.57 ±69.9 841.56 ±132.7 814.92 ±98.9 650.08 ±62.2 732.90 ±81.8 816.42 ±118.9 724.62±93.1 
6 weeks        




819.45±48.2 1023.32±129.4 1146.34±235.1 956±170.5 1006±206.9 1154.23±203.0 963±134.0 
Slow release pellets delivered 0 (Placebo) or 0.1 mg LPS/kg bw/d (LPS).  Baseline animals received only AIN-93M (control) diet.  Dietary treatments were: 
control diet, control diet with low (LPS/LDP) or high (LPS/HDP) dose dried plum added (low = 5% or high = 25%, w/w), control diet with comparable dose of 
polyphenolic compounds as low (LPS/LPP) and high (LPS/HPP) dose dried plum, or simvastatin (LPS/Statin) as a positive control (25 mg/kg diet).  Dietary 
treatments started after the baseline sacrifice (4 weeks post pellet implantation) and were maintained for 2 or 6 weeks.  
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Table 9.  Histological Scoring of the Myocardium 2 Weeks Post Dietary Treatment of the Large and Small Arteries and Arterioles 
 
Large Artery  Small Artery Large Arteriole Small Arteriole 
Scoring Category  0  1  2  3    0  1  2  3     0  1  2  3    0  1  2  3  
Treatment Groups 
Placebo (%)  100  ₋  ₋  ₋ 100  ₋  ₋  ₋         100     ₋   ₋              100   ₋  ₋         ₋
LPS (%)  100  ₋  ₋  ₋ 100  ₋ ₋ ₋ 100  ₋  ₋ ₋ 100  ₋ ₋ ₋
LPS+LPP (%)  100  ₋  ₋  ₋ 100  ₋  ₋  ₋  100  ₋  ₋  ₋  100  ₋  ₋  ₋  
LPS+HPP (%)  100  ₋  ₋  ₋ 100  ₋  ₋  ₋  100  ₋  ₋  ₋  100  ₋  ₋  ₋  
LPS+LDP (%)  100  ₋  ₋  ₋ 100  ₋ ₋ ₋ 100  ₋  ₋ ₋ 100  ₋ ₋ ₋
LPS+HDP (%)  100  ₋  ₋  ₋ 100  ₋ ₋ ₋ 100  ₋  ₋ ₋ 100  ₋ ₋ ₋
LPS+Statin (%)  100  ₋  ₋  ₋ 100  ₋ ₋ ₋ 100  ₋  ₋ ₋ 100  ₋ ₋ ₋
 
Large and small arteries and arterioles (n=6) were scored 0 through 3 based on severity of narrowing of the vessel (0 indicated no observed narrow and 3 was 
severe). 
 51
Table 10. Histological Scoring of the Myocardium 2 Weeks Post Dietary Treatment for Cellular Infiltration and Infarction 
 
Lymphocyte Infiltration PMN Infiltration  Infarction   Mast Cells  
Scoring Category 0 1 2 3   0 1 2 3   0 1   0 1 2 3 
Treatment Groups 
Placebo (%) 100 
₋ 
₋ ₋ ₋ 100 ₋ ₋ ₋ 100 ₋ 67 33 ₋ ₋ 
LPS (%) 67 33 ₋ 100 ₋ ₋ ₋ 100 ₋ 17 50 33
₋
 ₋
LPS+LPP (%) ₋ 83 17 ₋ 100 ₋ ₋ ₋ 100 ₋ 17 83 ₋
LPS+HPP (%) ₋ 33 67 ₋ 100 ₋ ₋ ₋ 100 ₋ ₋ 67 33 ₋
LPS+LDP (%) 17 50 33 ₋ 100 ₋ ₋ ₋ 100 ₋ 17 83 ₋ ₋
LPS+HDP (%) 67 33 ₋ ₋ 100 ₋ ₋ ₋ 100 ₋ 50 50 ₋ ₋ 
LPS+Statin (%) 67 33 ₋ ₋ 100 ₋ ₋ ₋ 100 ₋ 33 67 ₋ ₋
Infiltration was scored based on a 0-3 scale with 0 indicating no infiltration and 3 significant infiltration of lymphocytes and polymorphonuclear cell 
PMN.  Infarction was scored based on the absence (0) or presence (1) of incident (n=6). 
 
Lymphocyte Infiltration: 
Placebo vs. LPS (p=0.0025) 
LPS vs. HDP (p=0.0357); LPS vs. Statin (p=0.0357) 
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Table 11. Histological Scoring of the Myocardium 6 Weeks Post Dietary Treatment of the Large and Small Artery and 
Arteriole 
 
 Large and small arteries and arterioles (n 6) we e scored 0 through 3 ased on se erity of narrowing o the ve sel (0 ndicated no observed narro
and 3 was severe). 
= r b  v f s  i w 
Large Artery   Small Artery    Large Arteriole Small Arteriole  
Scoring Category 0 1 2 3   0 1 2 3   0 1 2 3   0 1 2 3 
Treatment Groups 
    Placebo (%) 100 
₋ 
₋ ₋ ₋ 1 0 0
₋
₋ ₋ ₋ 1 0 0
₋ 
₋ ₋ ₋ 1 0 0
₋
₋ ₋ ₋ 
    LPS (%) 1 0 0
₋ 
₋ ₋ 1 0 0
₋ 
₋ ₋ 50 50 ₋ 50 33 17
₋ 
 
    LPS/LPP (%) 100 ₋ ₋ 100 ₋ ₋ 66 17 17
₋
 ₋ 50 33 17
₋
 
    LPS/HPP (%) 100 ₋ ₋ ₋ 100 ₋ ₋ ₋ 66 33 ₋ 17 83 ₋
    LPS/LDP (%) 100 ₋ ₋ ₋ 100 ₋ ₋ ₋ 17 8
₋ 
3 ₋ ₋ ₋ 100 ₋ ₋ 
    LPS/HDP (%) 100 ₋ ₋ ₋ 100 ₋ ₋ ₋ 100 ₋ ₋ 50 50 ₋ ₋ 
    LPS/Statin (%) 100 ₋ ₋ ₋ 100 ₋ ₋ ₋ 100 ₋ ₋ ₋ 50 50 ₋ ₋ 
 
Large and Small Artery: 
Placebo vs. LPS (p=0.0025) 
LPS vs. LPP (p=0.0025); LPS vs. HPP (p=0.0025); LPS vs. LDP (p=0.0025); LPS vs. HDP (p=0.0025); LPS vs. Statin (p=0.0025) 
Large Arteriole: 
Placebo vs. LPS (p=0.0025) 
LPS vs. LPP (p=0.0498); LPS vs. HPP (p=0.0273); LPS vs. HDP (p=0.0025); LPS vs. Statin (p=0.0025) 
Small Arteriole: 




Table 12. Histological Scoring of the Myocardium 6 Weeks Post Dietary Treatment for Cellular Infiltration and Infarction 
Lymphocyte Infiltration PMN Infiltration Infarction   Mast Cells 
Scoring Category 0 1 2 3   0 1 2 3   0 1   0 1 2 3 
Treatment Groups 
    Placebo (%) 1
₋ 
00 ₋ ₋ ₋ 100 ₋ ₋ ₋ 100 ₋ 1
₋ 
00 ₋ ₋ ₋ 




3 ₋ ₋ 100 ₋ ₋ 100 ₋ 
    LPS+LPP (%) 17 50 33 100 ₋ ₋ 100 ₋ ₋ 50 50 ₋ 
    LPS+HPP (%) 1
₋ 
7 50 33 ₋ 100 ₋ ₋ ₋ 100 ₋ 1
₋ 
7 17 66 ₋
    LPS+LDP (%) 67 33 ₋ 100 ₋ ₋ ₋ 100 ₋ 67 33 ₋ 
    LPS+HDP (%) 3
₋ 
3 50 17 ₋ 100 ₋ ₋ ₋ 100 ₋ 1
₋ 
7 66 17 ₋ 
    LPS+Statin (%) 17 83 ₋ 100 ₋ ₋ ₋ 100 ₋ 33 67 ₋ 
Infiltration was scored based on a 0-3 scale with 0 indicated no observed infiltration and 3 indicative of many cells.                 Infarction was scored 
based on the absence (0) or presence (1) of incident (n=6). 
Lymphocyte Infiltration: 
 
Placebo vs. LPS (p=0.0025) 
LPS vs. LPP (p=0.0252); LPS vs. HPP (p=0.0252); LPS vs. LDP (p=0.0094); LPS vs. HDP (p=0.0112); LPS vs. Statin (p=0.0131) 
Mast Cells: 
Placebo vs. LPS (p=0.0025) 
LPS vs. HDP (p=0.0138) 
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Table 13. Histological Scoring of the Aorta Following 2 or 6 Weeks of Dietary Treatment 
 
Aorta Mean Score 
2 weeks 6 weeks 
   Placebo  0.00 ± 0.00 0.00 ± 0.00a 
   LPS 0.17 ± 0.17 6.83 ± 0.75b 
   LPS+LPP 0.00 ± 0.00 2.17 ± 0.40c 
   LPS+HPP 0.00 ± 0.00 1.50 ± 0.62c 
   LPS+LDP 0.00 ± 0.00 2.33 ± 0.42cd 
   LPS+HDP  0.00 ± 0.00 0.83 ± 0.48ac 
   LPS+Statin 0.00 ± 0.00 0.00 ± 0.00ac 
Scores of the aorta (n=6) were calculated by taking the mean of 3 parameters; thickening of the wall (0-3), thinning of the wall (0-3), and arthermatous plaque (0-3).  
In all cases 0 indicated no observed event and 3 indicated the severity of observed event.  Within a column, values that do not share the same superscript are 



























Figure 2.  Bone mineral density (BMD) of excised tibia. Baseline animals had either placebo pellet (0.0 μg LPS/day) or an LPS pellet 
delivering 0.1 mg LPS/kg/d, and maintained on control diet for 4 weeks.  Dietary treatments started after baseline and were 
maintained on control AIN-93 (Control), control diet with low (LDP) or high dose dried plum (HDP) added (low = 5% or high = 25%, 
w/w), control diet with comparable dose of polyphenolic compounds as low (LPP) and high dose dried plum (HPP), or simvastatin 





Figure 3. Baseline microarchitectural parameters of trabecular bone in the proximal tibial metaphysis. Parameters assessed by micro-
CT were (A) bone volume/total volume (BV/TV), (B) trabecular number (TbN), (C) thickness (TbTh), and (D) separation.  Bars 






 Figure 4.  2 week microarchitectural parameters of trabecular bone in the proximal tibial metaphysic.  Trabecular bone parameters 
include (A) bone volume/total volume (BV/TV), (B) trabecular number (TbN), (C) trabecular thickness (TbTh) and (D) trabecular 




Figure 5.  6 week microarchitectural parameters of trabecular bone in the proximal tibial metaphysisSix week microarchitecture 
parameters of trabecular bone observed in the proximal tibia including (A) bone volume/total volume (BV/TV), (B) trabecular number 




Figure 6. Gene expression of inflammatory mediators gene expression of the pro-inflammatory mediators (A) tumor necrosis factor 
(TNF)-α, and (B) interleukin (IL)-6, as well as the anti-inflammatory cytokine (C) IL-10 at baseline. Bars represent the mean SE for 




Figure 7.  Relative gene expression of key genes involved in bone resorption; (A) receptor activator of NF-κB ligand (RANKL), the 
decoy of RANKL, (B) osteoprotegerin (OPG), the ratio of (C) RANKL/OPG, and (D) tartrate resistant acid phosphatase (TRAP).  































Figure 8. Bone formation was analyzed at baseline by assessing the gene expression of alkaline specific phosphatase (ALP).  Bars 




Figure 9.  Inflammatory mediators at 2 weeks post dietary treatments, gene expression of common mediators involved in 
inflammation, (A) tumor necrosis factor (TNF)-α, and (B) interleukin (IL)-6, and (C) IL-10. Bars represent the mean SE for each 





Figure 10.  Alterations in gene expression following 2 weeks of  dietary treatment; (A) receptor activator of NF-κB ligand (RANKL), 
the decoy of RANKL, (B) osteoprotegerin (OPG), the ratio of (C) RANKL/OPG, and (D) tartrate resistant acid phosphatase (TRAP).  
Bars represent the mean SE for each treatment group.  Bars that share the same superscript letter are not statistically different from 





Figure 11.  Expression of key genes in bone formation at 2 weeks following dietary treatments by assessing the gene expression of 
(A) alkaline specific phosphatase (ALP) and (B) insulin like growth factor (IGF)-1.  Bars represent the mean SE for each treatment 
group.  Bars that share the same superscript letter are not statistically different from each other (p<0.05). 




Figure 12.  Inflammatory mediators at 6 weeks post dietary treatments, gene expression of common mediators involved in 






Figure 13.  Alterations in gene expression following 6 weeks of dietary treatment; (A) receptor activator of NF-κB ligand (RANKL), 
the decoy of RANKL, (B) osteoprotegerin (OPG), the ratio of (C) RANKL/OPG, and (D) tartrate resistant acid phosphatase (TRAP).  
Bars represent the mean SE for each treatment group.  Bars that share the same superscript letter are not statistically different from 


































Figure 14.  Gene expression of alkaline phosphatase (ALP) following 6 Weeks of dietary treatment.  Bars represent the mean SE for 

















The purpose of the current study was to determine if dried plum’s polyphenols are 
able to reverse the skeletal and vascular pathology previously observed  in a model of 
chronic low-grade inflammation (21, 22).  We have demonstrated that this model of 
chronic low grade inflammation induces bone loss of the tibia and femur, as indicated by 
decreased BMD, and compromised trabecular bone microarchitecture (21, 46).  In the 
present study, however, we were unable to reproduce these changes in tibial BMD, or 
trabecular microarchitectural parameters at baseline, and 2 and 6 weeks after dietary 
treatments.  Based on these results, we conclude that the LPS pellet did not produce 
inflammation-induced bone loss at the skeletal site tested as previously indicated.  A 
potential explanation for this is the fact that in this study only one skeletal site (i.e. the 
tibia), was used for the assessment of bone quality, as compared to the other studies 
where multiple sites had been used (21, 46).  Based on the results of previous studies (21, 
46), we anticipated that the tibia was a reasonable site to assess the skeletal changes, and 
had allocated other long bone specimens for other analyses.  By limiting ourselves to this 
one site, we may have induced an inflammatory more apparent responses at other sites 
(i.e. femur or vertebra), but were unable to evaluate. 
 In the current study one of the objectives was to determine the mechanism by
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which chronic low grade inflammation induces bone loss and cardiovascular pathology.  
In a prior study (23), 30 days after pellet implantation produced a significant increase in 
the pro-inflammatory cytokine, TNF-α protein expression of the tibia. Therefore, we 
expected that in the current study that LPS-treated animals’ TNF-α expression would be 
increased in the bone at the transcriptional level.  However, at baseline (i.e. 4 weeks post 
LPS pellet implant) there was no change in the relative TNF-α RNA abundance 
compared to the placebo group.  Gene expression of IL-6 was also assessed, given that 
this pro-inflammatory cytokine is up-regulated during states of inflammation and may 
remain up for extended periods of time (84), however, no differences were observed in 
groups receiving the LPS compared to the placebo pellets.  At 2 weeks post dietary 
treatment, the placebo and LPS control did not have different levels of TNF-α gene 
expression.  Even though similar levels of TNF-α in the placebo and LPS group was not 
expected, the high dose of polyphenols was able to attenuate TNF-α expression compared 
to placebo and LPS controls.  Both doses of dried plum decreased the gene expression of 
TNF-α compared to the placebo control.  Due to dried plum’s high polyphenol content 
(31) and the fact that polyphenols are known to possess potent anti-inflammatory 
properties (151), the dietary treatment’s ability to down-regulate TNF-α production 
seems in line with previous findings (23).   
 This trend did not continue at 6 weeks as there was no difference in TNF-α 
expression, or any other cytokines.  Although we did not observe the expected results 
with regards to the LPS pellet, dried plum’s polyphenols and the whole fruit were able to 
down-regulate TNF-α to some extent, which further supports the potential potency of this 
dietary intervention. 
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To determine if dried plum’s polyphenols were acting via anti-resorptive 
pathways, RANKL gene expression was studied at 2 weeks post treatment.  The placebo 
and LPS groups on the control diet demonstrated no alterations in RANKL gene 
expression.  However, the low and high dose of dried plum’s polyphenols and the low 
and high doses of whole fruit dried plum tended to decrease RANKL expression 
compared to the placebo control.  Although this observation did not reach the level of 
statistical significance, it seemed as though dried plum and its polyphenols were able to 
exert some beneficial effect on RANKL gene expression.  After 6 weeks of dietary 
treatment dried plum and its polyphenols did exert beneficial effects on RANKL gene 
expression.  In the LPS-control cohort, RANKL gene expression was up-regulated 
compared to the placebo controls.  The groups receiving the high dose of dried plum’s 
polyphenols and the low dose of dried plum were able down-regulate this response.  
Previous studies have suggested that dried plum’s polyphenols can attenuate RANKL 
gene expression (34, 36), and our results not only support this conclusion, but also 
indicate the possibility that dried plum’s polyphenols are able to suppress bone 
resorption.   
In addition to the lack of an effect of LPS on bone structural properties and gene 
expression and the limited response to dried plum and its polyphenols, it should also be 
noted that alterations at the tissue level were not observed with the pharmacological 
agent, simvastatin.  We had chosen to use simvastatin as a positive control in this study 
based on evidence that this pharmacological agent has known anti-inflammatory 
properties (27) and exerts beneficial effects on the skeletal (26) and cardiovascular 
systems.  There were no alterations observed in the statin group other than its ability to 
 73
down-regulate IGF-1, which was not expected based on previous studies (27).  We 
anticipated that simvastatin would  increase BMD or BV/TV, and up-regulated ALP 
which is associated with  bone formation (29).  At the very least we expected simvastatin 
to down-regulate TNF-α and IL-6 (27, 30), however this was not observed.  Due to the 
lack of response by the inflammatory mediators, TNF-α and IL-6, it seems as though we 
were unable to induce chronic-low grade inflammation in the bone to the extent we had 
in prior studies. 
A potential issue that should be addressed is the composition of the bone 
specimen (i.e. whole bone vs flushed bone or bone marrow) used for the evaluation of  
mRNA may have impacted the real time-PCR results (152).  In the present study we used 
whole femurs to extract RNA.  Some studies (152, 153) have used either the distal 
metaphyseal region of the femur or flushed bone, while others have used whole bone 
specimens.  Although the same bone is used, it is apparent that the presence of bone 
marrow may dilute the findings relative to genes expressed specifically by osteoclasts and 
osteoblasts.  However, the fact that gene expression levels for TNF-α and IL-6 were not 
altered combined with the fact that skeletal changes were not observed suggests that this 
may not be the case. 
Although the skeletal system did not seem to respond as expected, vascular 
pathology was observed in the aorta and hearts of these specimens.  Histological staining 
of the myocardium after 2 weeks of dietary treatment showed that the high dose of dried 
plum and statin therapy were able to decrease the frequency of lymphocyte infiltration, 
which is indicative of microvascular disease.  After 6 weeks of treatment all dietary 
interventions were able to totally prevent the large and small artery narrowing induced by 
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LPS of such vessels and reduced PMN infiltration.  Lymphocyte infiltration was 
decreased in LPS model after 6 weeks of treatment with all dietary treatments.  These 
results suggest that in this study the cardiovascular system was more responsive to the 










Summary of Findings 
Several population-based studies have indicated that a relationship exists between 
the pathophysiology of osteoporosis and cardiovascular disease.  Chronic elevation of 
inflammatory mediators, such as tumor necrosis factor (TNF)-α and members of the TNF 
receptor superfamily of proteins such as the RANKL and its soluble decoy receptor, 
OPG, have been proposed as playing a pivotal role in concurrent osteoporosis and 
atherosclerosis.  Previously, our laboratory has shown that dietary supplementation with 
dried plum and its polyphenols down-regulate inflammatory mediators such as TNF-α 
and RANKL in vitro and in models of gonadal hormone deficiency (35, 36).  The aim of 
the current study was to induce simultaneous occurrence of bone loss and vascular 
pathology by chronic low grade inflammation, and to determine the protective effect 
dried plum’s polyphenols exert in vivo.  This study utilized 12-wk-old C57BL/6 male 
mice (n=192) that were implanted with pellets designed to deliver either 0.0 or 0.1 mg 
LPS/kg bw/d and randomly assigned to one of the following dietary treatments:  Placebo-
control (AIN-93M) diet, LPS Control , control diet supplemented with low (LDP) or high 
dose dried plum (HDP) (low = 5% or high = 25%, w/w DP added), control diet with 
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comparable dose of polyphenolic compounds as low (LPP) and high dose dried plum 
(HPP), or simvastatin (Statin) as a positive control (25 mg/kg diet).  All dietary 
treatments initiated after the 4 week period to induce bone loss and vascular disease and 
were maintained for either 2 or six weeks.  We have reported that no inflammation-
induced changes in bone mass, trabecular or cortical microarchitecture, and bone 
biomechanical properties at baseline, 2 or 6 weeks were observed in this study.  
However, in the cardiovascular system we did observe vascular changes indicative of 
microvascular disease and that after 6 weeks of dietary intervention dried plum’s 
polyphenols were able to protect from observed pathology.  
 
Conclusions 
Hypothesis:  Polyphenols extracted from dried plum will reverse the bone loss and 
vascular pathology induced by chronic low grade inflammation by reducing key 
inflammatory mediators involved in the pathophysiology of osteoporosis and CVD.   
Based on the results of this study we reject our proposed hypothesis due to the 
fact that we were unable to observe bone loss in any of our time points using the LPS 
pellet model.  Our results do suggest, however, that the LPS pellet did induce vascular 
pathology, and histology revealed that all of our treatment groups were able to protect 
against this induction.  These findings suggest that in this study the cardiovascular system 






Recommendations for Further Research 
Although we were unable to demonstrate that dried plum’s polyphenols reversed 
skeletal deterioration in response to chronic inflammation in vivo, this model may have 
induced bone loss at another site.  A similar study should be designed to test multiple 
sites at which bone loss may occur (i.e. spine, femur), and could therefore truly determine 
the degree dried plum’s polyphenols had an effect.  Furthermore, there remains the 
possibility that the pellet preparation did not allow for the appropriate delivery of the 
dose of LPS. This statement is made based on the fact that there was not response in the 
bone and even the cardiovascular changes were not as pronounced as we have previously 
observed.  However, we are unable to determine if the pellets were problematic at this 
point.  If in fact, there have been alterations in LPS (or other contaminate) dose, this 
would have dramatically affected our results.  A method to pre-test the response may 
prevent this from occurring in the future.  One of the important features of an animal 
model system is that it provides reproducible results.  
The possibility that dried plum’s polyphenols are able to protect against vascular 
pathology may open many doors for additional research to begin to assess the practicality 
of such alternative treatment options.  Different combinations of foods rich in 
antioxidants, combined with lower doses of pharmacological agents may be achievable, 
and offer patients the same beneficial effects without undesirable side-effects.  Such 
studies evaluating the efficacy of dried plums and their bioactive components alone and 
in combination with low dose pharmacological interventions warrant further 
investigation. 
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Figure 16. The bone turnover mediator TRAP was assessed using Elisa kit on mouse 




Figure 17. A portion of the liver was used to extract protein to be used to asses any 
observable alterations in HMG-CoA Reductase.  A small portion of the liver was 
homogenized using a VWR Power MAX homogenizer and lysis buffer.  Microsomal 
protein was isolated by centrifugation.  The Beckman Coulter DU800 spectrophotometer 
was used to determine protein concentration and SDS-PAGE and Immunoblot was 
performed.  Anti-HMG CoA reductase antibody (Millipore, Temecula, CA) was used for 
incubations to determine protein level of HMG-CoA reducatse among groups (B), anti-
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